Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application

Alessandra Ciucci1,2 · Marianna Buttares1,2 · Anna Fagotti2,3 · Giovanni Scambia2,3 · Daniela Gallo1,2

Received: 17 March 2022 / Revised: 5 May 2022 / Accepted: 23 May 2022 / Published online: 16 June 2022 © The Author(s) 2022

Abstract
Despite many improvements in ovarian cancer diagnosis and treatment, until now, conventional chemotherapy and new biological drugs have not been shown to cure the disease, and the overall prognosis remains poor. Over 90% of ovarian malignancies are categorized as epithelial ovarian cancers (EOC), a collection of different types of neoplasms with distinctive disease biology, response to chemotherapy, and outcome. Advances in our understanding of the histopathology and molecular features of EOC subtypes, as well as the cellular origins of these cancers, have given a boost to the development of clinically relevant experimental models. The overall goal of this review is to provide a comprehensive description of the available preclinical investigational approaches aimed at better characterizing disease development and progression and at identifying new therapeutic strategies. Systems discussed comprise monolayer (2D) and three-dimensional (3D) cultures of established and primary cancer cell lines, organoids and patient-derived explants, animal models, including carcinogen-induced, syngeneic, genetically engineered mouse, xenografts, patient-derived xenografts (PDX), humanized PDX, and the zebrafish and the laying hen models. Recent advances in tumour-on-a-chip platforms are also detailed. The critical analysis of strengths and weaknesses of each experimental model will aid in identifying opportunities to optimize their translational value.

Keywords Primary EOC cells · Organoids · Patient-derived EOC explants · Patient-derived EOC xenografts · Humanized mouse models · GEMMs

Abbreviations

2D Two-dimensional
3D Three-dimensional
3R Replacement, Reduction and Refinement
AdCre A replication-deficient adenovirus altered to express Cre under the control of the CMV promoter
Akt Thymoma viral proto-oncogene 1
AMHR2 Anti-Mullerian hormone receptor type 2
Apc Adenomatous Polyposis Coli
Arid1a AT-rich interactive domain 1A
ASC Adult stem cells
ATCC American Type Culture Collection
BOT Borderline ovarian tumors
BRAF B-Raf proto-oncogene, serine/threonine kinase
BRCA1 Breast Cancer gene 1
BRCA2 Breast Cancer gene 2
BRCA1/2 mutations
CAN Copy-number alteration
CBA CellBank Australia
CCC Clear-cell carcinoma
CCLE Cancer Cell Line Encyclopedia
CCNE1 Cyclin E1
CCR4 C–C chemokine receptor type 4
| Abbreviation | Definition |
|--------------|------------|
| CDXs         | Cancer cell line-derived xenografts |
| CLASTR       | Cellosaurus STR similarity search tool |
| CNV          | Copy-number variation |
| COSP         | Calculator for Ovarian Subtype Prediction |
| CRISPR/Cas9  | Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 |
| CSC          | Cancer stem cells |
| DEGs         | Differentially expressed genes |
| DMBA         | 7,12-Dimethylbenz[a]anthracene |
| DSMZ         | Deutschen Sammlung von Mikroorganismen und Zellkulturen |
| EBV          | Epstein–Barr virus |
| ECACC        | European Collection of Cell Cultures |
| ECM          | Extracellular matrix |
| EGF          | Epidermal growth factor |
| EMBL-EBI     | European Molecular Biology Laboratory-European Bioinformatics Institute |
| EnOC         | Endometrioid ovarian carcinoma |
| EOC          | Epithelial ovarian cancer |
| EPO          | In vivo electroporation |
| ESC          | Embryonic stem cells |
| FTE          | Fallopian tube epithelial |
| GEMMs        | Genetically engineered mouse models |
| GM-CSF       | Granulocyte macrophage colony-stimulating factor |
| HDRA         | Histoculture drug response assay |
| HGSOCS       | High-grade serous ovarian carcinoma |
| HR           | Homologous recombination |
| HSC          | Hematopoietic stem cells |
| LhTERT       | Human telomerase reverse transcriptase |
| HPV          | Human Papilloma Virus |
| huPBMC       | Human peripheral blood mononuclear cell |
| IB           | Intrabursal |
| IDS          | Interval debulking surgery |
| IP           | Intraperitoneal |
| iPSC         | Induced pluripotent stem cells |
| IVIS         | In Vivo Imaging System |
| JCRB         | Japanese Collection of Research Bioresources |
| KITLG        | KIT ligand |
| KRAS         | Kirsten rat sarcoma virus |
| LGSOCs       | Low-grade serous ovarian carcinoma |
| Lkb1         | Liver kinase B1 |
| MCAs         | Multicellular aggregates |
| MEK1         | MAP (Mitogen-Activated Protein) Kinase/ERK (Extracellular Signal-Regulated Kinase) Kinase 1 |
| MEK2         | MAP (Mitogen-Activated Protein) Kinase/ERK (Extracellular Signal-Regulated Kinase) Kinase 2 |
| MISIIR       | Mullerian inhibiting substance type II receptor |
| MOCA         | Mucinous ovarian carcinoma |
| MOSE         | Mouse ovarian surface epithelial |
| MOVCAR       | Murine ovarian carcinoma |
| MRI          | Magnetic resonance imaging |
| MTT          | 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide |
| MYC          | MYC proto-oncogene, bHLH transcription factor |
| Myc          | Myelocytomatosis oncogene |
| NACT         | Neoadjuvant chemotherapy |
| Nf1          | Neurofibromin 1 |
| NOD          | Non-obese diabetic |
| NRG          | NOD-Rag1/-IL2RgammaC-null |
| NSG          | NOD/SCID/IL2Rγ null |
| NSGS         | NSG-SGM3 |
| OC           | Ovarian cancer |
| OSE          | Ovarian surface epithelial |
| OTME         | Ovarian tumour microenvironment |
| Ovgp1        | Oviductal glycoprotein 1 |
| PARP         | Poly (ADP-ribose) polymerase |
| Pax8         | Paired box gene 8 |
| PD-1         | Programmed cell death 1 |
| PDE          | Patient-derived explant |
| PD-L1        | Programmed cell death ligand 1 |
| PDO          | Patients-derived organoid |
| PDX          | Patient-derived xenograft |
| PDS          | Primary debulking surgery |
| PIK3CA       | Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha |
| Pten         | Phosphatase and tensin homolog |
| Rb           | Retinoblastoma protein |
| RNA          | Ribonucleic acid |
| SC           | Subcutaneous |
| SCF          | Stem cell factor |
| SCID         | Severe combined immunodeficiency |
| SRC          | Subrenal capsule |
| STR          | Short tandem repeat |
| SV40         | Simian virus 40 |
| TA           | Transnational Access |
| TAM          | Tumor-associated macrophages |
| TIL          | Tumor-infiltrating lymphocytes |
| TME          | Tumor microenvironment |
| TP53         | Tumor protein p53 |
| Trp53        | Transformation-related protein 53 |
| UKCTOCS      | UK Collaborative Trial of Ovarian Cancer Screening |
| US           | Ultrasound |
| VAF          | Variant allele frequency |
Background

Worldwide, estimated 313,959 new cases of ovarian cancer (OC) and almost 207,252 cancer deaths occurred in 2020 [1]. Therefore, despite the last years have seen many important advances in OC with newly identified therapeutic opportunities, the disease remains the most deadly of all gynaecological cancers [2]. Disappointingly, long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) has also provided evidence that neither annual multimodal screening nor annual transvaginal ultrasound screening approach significantly reduced deaths from ovarian and tubal cancer [3].

Ovarian cancer encompasses a collection of neoplasms with distinct epidemiological and genetic risk factors, precursor lesions, patterns of spread, molecular events during oncogenesis, response to chemotherapy, and prognosis [4]. Over 90% of ovarian malignancies are categorized as epithelial ovarian cancers (EOC), and currently, five main types are identified: high-grade serous (HGSOC 70%), low-grade serous (LGSOC < 5%), mucinous (MOC 3%), endometrioid (EnOC 10%), and clear-cell (CCC 10%) carcinomas [4]. High-grade serous ovarian cancer represents the most common histologic type of EOC. It typically presents at advanced stage (III–IV) and, despite the initial response to surgical debulking and first-line therapy with carboplatin and paclitaxel (with or without bevacizumab), most tumors eventually develop drug resistance, with a 5-year survival generally below 30% [5].

Future high-quality translational research on EOC is therefore expected to focus on improving understanding of disease biology, identifying correlates of response and resistance to therapy and on providing new target cancer therapies, ultimately developing more effective ways to detect and treat this lethal disease. Proper selection of preclinical models and design of studies is mandatory for achieving such ambitious objectives, making preclinical data translatable to the clinic. This review is intend to offer a

**Fig. 1** An overview of preclinical models of Epithelial Ovarian Cancer (EOC). PDE patient-derived explants, PDX patient-derived xenograft, humPDX humanized PDX, GEMMs genetically engineered mouse models. This figure was created with BioRender.com

![PRECLINICAL MODELS OF EPITHELIAL OVARIAN CANCER](image-url)
comprehensive overview of preclinical models available for the study of EOC (Fig. 1).

**In vitro and ex vivo models**

**Established cancer-derived cell lines**

Established cancer-derived cell lines have provided invaluable experimental tools for many decades to study cancer biology, identify correlates of response and resistance to existing therapy, and test the therapeutic efficacy of potential new treatments. Established cell lines are indeed relatively easy to manipulate, inexpensive to use and provide rapid experimental results. However, there have been questions about how relevant the research performed on these cell lines is, particularly with regard to misidentification and contamination of the cell line (a list of cell lines that are known to be cross-contaminated or otherwise misidentified can be accessed here: https://iclac.org/databases/cross-contaminations/). Besides, prolonged cell culture is likely to induce the occurrence of secondary genomic changes, including copy-number variations and transcriptomic drifts, or selection of some specific clones, elements that can bias the experimental results [6, 7]. Actually, although it appears that at the genomic level driver mutations are retained, literature data suggest that cancer cell lines resemble each other more than their original clinical samples, this limiting their usefulness and impacting the final overview [6, 7]. Because of these reasons, responses of some cell lines to drug, either in vitro or in vivo preclinical models, were not recapitulated in many clinical trials, limiting the use of cell lines as a preclinical model [8]. In this context, the requirements for cell line authentication by short tandem repeat (STR) profiling have become stringent. CLASTR, the Cellosaurus STR similarity search tool (https://web.expasy.org/cellosaurus-str-search/) [9] enables users to compare STR profiles with those available in the Cellosaurus cell line knowledge resource, thus aiding researchers in the process of cell line authentication. Finally, contamination by mycoplasma and other microorganism has to be excluded before using.

In the context of EOC, the now well-recognized genomic heterogeneity of this disease adds further complexity to this already complex picture. Accordingly, in the last decade, several studies have been carried out to evaluate the suitability of the different available cell lines as representative models for the distinct EOC subtypes. Worldwide, there are about 100 ovarian cancer cell lines and near 70 of these are available at different cancer cell line bank, including ATCC (American Type Culture Collection, USA, https://www.atcc.org/); ECACC (European Collection of Cell Cultures, UK, https://www.phe-culturecollections.org.uk/collections/ecacc.aspx); DSMZ (Deutsches Sammlung von Mikroorganismen und Zellkulturen, Germany, https://www.dsmz.de/); RIKEN (RIKEN Bioresource Center CELL BANK, Japan, https://cell.brc.riken.jp/en/); JCRB (Japanese Collection of Research Bioresources Cell Bank, Japan; http://cellbank.nibio.go.jp/); CBA (CellBank Australia; http://www.cellbankaustralia.com/) [10, 11]. Only recently, however, some of the EOC cell lines from the Japanese collections have been made available from supplier located in Europe.

Noteworthy, a pivotal study by Domcke and colleagues [12] demonstrated that the most frequently used EOC cell lines seem for the most part badly suited for investigating HGSOC, the most prevalent EOC subtype, whereas the cell lines that more closely resemble these tumors are rarely used in laboratories. Using available molecular profiles of cell lines from the Cancer Cell Line Encyclopedia (CCLE) (47 cell lines examined) and comparing tumour sample data obtained from TCGA, the authors proved that significant differences exist in the molecular pattern between commonly used cell lines and HGSOC samples. To best differentiate between HGSOC and other EOC subtypes, they chose to evaluate both alterations typical of HGSOC (such as mutations in TP53 and BRCA1/2, and amplifications in other genes including CCNE1, MYC, PIK3CA, and KRAS) and also mutations in a subset of genes classically altered in other EOC subtypes (e.g., KRAS and BRAF). Results obtained showed that the most recurrently mutated genes in HGSOC were also mutated in a significant fraction of cell lines; TP53 was found mutated in 62% of cell lines, and BRCA1 and BRCA2 in 6% and 9%, respectively. A similar degree of copy-number alteration (CNA) was also demonstrated. However, among the commonly used models for HGSOC subtype, three cell lines, namely IGROV-1, SKOV-3, and A2780, had little profile similarity to the tumors, the latter also showing intact TP53 [12]. Conversely, other cells, including less commonly used lines, such as COV362, COV318, and OV-90, were reported to be likely/possibly high-grade serous [12]. Other studies were published thereafter with similar results. Beaufort and colleagues [10], through a comprehensive profiling of 39 commercially available cell lines, assigned half of them (20) as non-serous type, 14 as high-grade serous, and five as serous-type/low-grade serous. Different approaches for the classification of EOC cell lines have been proposed, including the use of predictive clinical algorithms, as Calculator for Ovarian Subtype Prediction (COSP) [13] and of a transcriptional classifier developed by trialing machine learning algorithms [14]. Notably, in line with observations by Domcke and colleagues [12], results from these latter studies questioned the use of SKOV-3, A2780, and IGROV-1 as models of HGSOC, classifying these lines as derived from endometrioid/clear-cell EOC, although some uncertainties still exist. Other cell lines, including OVCAR-3, OVCAR-4,
CAOV-3, KURAMOCHI, and OVSAHO, have been consistently classified as HGSOC [10, 12–14]. Table S1 shows the classification of a panel of EOC cell lines, according to the above-mentioned literature data.

With regard to HGSOCs, besides TP53 mutations occurring in about 96% of cases, BRCA1/2 germline and somatic mutations are detected in about 20–25% of patients [15, 16] and therefore, cell lines with BRCA1/2 mutations may be of particular relevance for some experimental studies. Mutations in BRCA1 have been described in the cell lines COV362, JHOS2, and UWB1.289 [12] (https://depmap.org/portal/ctle; https://cellmodelpassports.sanger.ac.uk/); likewise, BRCA2 mutations have been found in KURAMOCHI and PEO1 cell lines.

However, it is worthy to note that cells with BRCA deficiency do not survive well in standard cell culture conditions and this can induce a selective pressure for reversion of the original mutation. This has been demonstrated in PEO1 cells by Stronach and colleague [17] who identified a BRCA2 reversion mutation (5192A > T;5193C > G [Y1655L]) in unselected stock of PEO1, in line with the previous findings from Sakai and colleagues [18], who reported that the same mutation emerged following selection with cisplatin/PARP Poly (ADP-ribose) polymerase) inhibitors. Notably, sequence verification of our stocks of PEO1 has also identified this BRCA2 reversion mutation [c.4964_4965delinsTG (coverage: 1549/1653X: VAF:94%) p.(Tyr1655Leu)] (unpublished data). Cells with this mutation are homologous recombination competent and possibly exist as a sub-dominant population within the original PEO1 line, a condition that can alter cell growth and sensitivity to drugs.

Normal controls of cancer tissues are also required for comparative studies; both ovarian surface epithelial (OSE) cells and fallopian tube epithelial (FTE) cells represent cells of origin of HGSOC, while LGSOC are thought to evolve in a stepwise fashion from the OSE [19, 20]. Primary culture of normal cells, both OSE and FTE, is challenging due to the limited proliferative potential and early senescence or spontaneous transformation, in small cases. Different methods for culturing primary normal cells have been developed to obtain valuable experimental tools for studying transformation [21, 22]. However, their use is limited to single short-term and small-scale in vitro experimentation and the immortalization is necessary [22, 23]. The common immortalization process by induction of HPV16 E6/E7 and SV40 large T antigen expression, or in alternative hTERT, extends the lifespan of these cells, but is not sufficient for cell transformation. Importantly, immortalized OSE and FTE cells may be highly useful as control cells for OC research, especially for transformation assays in which they are transduced with different genetic alterations to reproduce the carcinogenesis process. Overall, studies evaluating disease biology and neoplastic progression may take advantage of these experimental tools, including the most appropriate model according to the specific histotype under investigation.

### Primary ovarian cancer cell lines

The establishment of primary, patient-derived, tumour cells provides a very important experimental system for better understanding EOC biology and mechanisms of therapy resistance, and for improving development of new drugs for personalized treatment. Indeed, despite having a limited lifespan and being slow-growing, primary EOC cells are valuable, because they preserve patient-cell features and can be associated with the clinicopathological data. On the other hand, immortalized cell lines, grown through serial passages, with genotypic and phenotypic changes, are less representative of the original tumour and their use might not be translationally relevant.

The isolation of primary EOC cells can be achieved using solid tumour specimens or patients' ascites with different methods [21]. To obtain single-cell suspensions from surgical biopsy, dissociation is the first step and three main dissociation techniques exist, based on chemical, mechanical or enzymatic processes [24]. Tissue dissociation is a critical issue, since, due to an excessive dissociation process, epithelial cells can lose their morphology. Besides, exerting excessive chemical or mechanical pressure on cells is a stressful factor that may significantly change the expression levels of genes. A major problem regarding the isolation of EOC cells directly from solid tumours is the presence of multiple cell types, namely erythrocytes and fibroblasts, and the composition of primary cultures varies, as function of tissue origin. These contaminating cells may be present at initial plating, but most of them are removed using appropriate enzymatic digestion and at the media change, leaving the adherent EOC cells [21, 25]. Clearly, it is particularly important to determine whether the cells recovered are representative of tumour and the percentage of cell contamination. EOC mainly typically express cytokeratins in their cytoplasm; therefore, cytokeratin immunostaining is used for the identification of epithelial cancer cells.

Ascites fluid can also be a valuable source of tumour cells, easily accessible following paracentesis from the patient. Isolation and culturing of primary cancer cells from ascites have become common, and different approaches have been developed [26]. The isolation occurs without mechanical or enzymatic digestion [21] and, under non-adherent conditions, cells grow in aggregates, preserving their molecular and phenotypic profiles. Notably, in physiological conditions, ascitic cells can appear as multicellular aggregates (MCAs) or single cells [21, 27], although the development of aggregates facilitates tumour cell survival, protecting them from anoikis, and contributing to secondary lesion
formation in peritoneal organs [28]. Latifi and colleagues [27] separated from ascites of HGSOC patients, two different populations: epithelial tumorigenic (non-adherent cells) with selective CSC-like markers and mesenchymal non-tumorigenic populations (tumour adherent), demonstrating that spheroids with cancer stem cell characteristics show a more aggressive metastatic and chemoresistant phenotype.

Culture of primary cancer cells is critical, due the slow growth capacity of cancer cells, the limited overall lifespan, as well as the non-tumour cells contamination of the culture, factors inducing a lack of reproducibility. Indeed, cancer cells frequently lose growth potential after some passages and go into crisis, suggesting that replicative senescence might be a crucial step in becoming a cell line under culture conditions. Recent findings have shown that primary EOC cells become growth-arrested after approximately five population doublings [29, 30], being their proliferative capacity homogenous across different histotypes [29]. Senescent cells, exhibiting biochemical and molecular signatures of senescence, were shown to be growth-arrested in the G1 phase of the cell cycle, the stage where the majority of nor-
senescence, were shown to be growth-arrested in the G1 cells, exhibiting biochemical and molecular signatures of

- Ince and colleagues [35], primary EOC cells undergo spontaneous senescence in a mosaic, telomere-dependent and telomere-independent manner. Finally, senescence in primary EOC obtained from ascites also occurs between the 2nd and 8th passages [32]. Therefore, to ensure a healthy and proliferative starting material, experiments on primary EOC cells should be performed within passages 2–4.

The medium for tumour primary cell cultures plays an important role for growing and maintaining them, without causing any genetic drift. Various nutrients and growth factors (epidermal growth factor, insulin, hydrocortisone, beta-
estadiol, and progesterone) may be added to the medium even if their addition can alter the growth and epithelial morphology of EOC cells [33, 34]. Ince and colleagues [35] successfully established 25 novel cell lines from primary OC with significant high rate using culture media and conditions optimized to each histological subtype. Notably, these established cells retained the genomic landscape, histopathology, and molecular features of the original tumours. Furthermore, the drug response of these cell lines correlated with distinct groups of primary tumours with different outcomes [35].

Overall, primary EOC cell lines by preservation of cell phenotypes, stemness, and heterogeneity of cancer subpopulations offer advantages not always attainable by established cell lines, thus representing a significantly improved platform to study human tumour pathophysiology and response to therapy.

Two- and three-dimensional cell culture models

The traditional 2D cell culture method is a well-known, inexpensive and relatively easy system to generate and maintain cell lines and to evaluate response to drug treatment. In 2D cell culture conditions, cells grow and expand two-dimensionally on the surface of cell culture dishes, thus taking a flat and elongated shape, being uniformly exposed to nutrients, growth factors, and test agents [36]. Although 2D cell culture is generally accepted and still used because of its simplicity and low cost, there are limitations associated with it. In this culture method, cell–cell and cell–extracellular environment interactions are not represented, gene and protein expression levels are often different compared to in vivo models, and analysis of response to cytotoxic drug treatment may overestimate drug efficacy. Indeed, many properties of organs and tumours, including tissue architecture, cell–cell and cell–matrix interactions, mechano-physical properties, and gene expression networks are not, or only partially, represented under 2D culture conditions. These limitations of the 2D systems have prompted research on alternative models, better able to mimic a natural tumour mass, such as three-dimensional (3D) culture systems. Therefore, switching from 2 to 3D cultures has been moved by the need to create cellular models that could better recapitulate the complexities of tumour biology. Besides, 3D models have been recognized as proper tools for drug discovery and screening.

Three-dimensional cell cultures are classified as scaffold-based or non-scaffold-based techniques [37]. Scaffold-based culture technologies provide physical support on which cells can aggregate, proliferate, and migrate; scaffolds can be of biological origin or synthetic, to mimic key properties of the extracellular matrix (ECM) [37]. More recently, this scaffold-based approach has been used by 3D bioprinting technique to create more complex models with well-defined architecture, composition, and high reproducibility [38]. On the other hand, the scaffold-free-based 3D systems occurs through self-aggregation of cells, with development of multicellular aggregates, commonly known as spheroids [39]. Spheroids can be obtained from established cell lines or patient-derived tissue samples, although not all primary tumour cells or conventional cell lines are capable of forming spheroids [40]. Heredia-Soto and colleagues [41] obtained spheroids from 16 commonly used, commercially available OC cell lines, with three different patterns for 3D cell growth. Some cell lines adopted a loose aggregate conformation (i.e., A2780, A2780cis, OVCAR-3, OAW28, PEA1, PEA2, PEO23, and TO14), others had a more compact aggregate and non-spherical structure (i.e., PEO1, PEO4, PEO6, and PEO14), and a third group of tight
spheroids had very well-defined perimeters (i.e., PEO16, OV56, SKOV-3, and 59 M). Overall, it has been reported that ovarian spheroids show morphological resemblance to multicellular aggregates in cancerous ascites [42]. Analysis of spheroid versus monolayer ovarian cancer cells has demonstrated differences in the expression of several biomarkers relevant to disease, which could alter the tumorigenic properties of the cells [43]. Overall, these findings support the hypothesis that ovarian cells in 3D culture are physiologically different from their 2D monolayer, indicating 3D growth more informative in studying the properties of EOC cell lines. Besides, these aggregates displayed a higher chemoresistance after paclitaxel and cisplatin treatment, when compared to 2D condition, mimicking the in vivo response [43]. Indeed, as a peritoneal metastasis, the access of chemotherapy agents to internal cells can be inhibited in the un-vascularized 3D spheroids due to their structure characterized by a metabolite density gradient, this possibly representing a mechanism of resistance in EOC [44, 45].

To mimic the cancer niche and the interactions between the tumour and its microenvironment, 3D co-culture models have been also established from cancer cell lines or primary cells, in combination with stromal cells as fibroblasts, endothelial, or immune cells. Recently, Long and colleagues [46], by co-culturing OC spheroids and tumour-associated macrophages (TAM) have shown that the interaction with TAM promotes the progression of OC. These findings support the translational relevance of such experimental models. Indeed, it is known that the most abundant population of tumour-infiltrating immune cells in EOC are TAMs, which have been demonstrated to play a critical role in development of tumour progression and chemoresistance [47–49].

Organoids

Organoids can be defined as 3D structures derived from stem cells of various organs and tissues. They are derived either from adult stem cells (ASC) or from pluripotent embryonic stem cells (ESC) and their synthetically induced counterparts, i.e., induced pluripotent stem cells (iPSC) [50]. This important feature denotes the major difference between spheroids and organoids; organoids originated from stem cells, whereas spheroids not.

Unlike other type of cancers, only a limited number of studies are available for patients-derived organoid (PDO) cultures from EOC. To establish PDOs from resected OC biopsies, the primary tumour tissue is initially digested by mechanical and enzymatic digestion followed by embedding cells into a specific matrix (such as Matrigel) and culturing medium, supplemented with a cocktail of growth factors and hormones for long-term maintenance. Different experimental protocols have been set up to obtain EOC organoids. A detailed description of methodological approaches is out of the scope of this review, but exhaustive information can be found in recent reviews [51, 52]. A critical aspect of organoid culture is certainly the definition of a growth factors cocktail, since differences in medium components are important to enhance the efficiency of kick-starting organoid cultures from individual patients. However, components of culture medium differ very much among different researchers. Indeed, according to Kopper and colleagues [53], a Wnt-conditioned medium may be essential on some cell lines, while detrimental in other cases, irrespective of the histotype considered. On the other hand, Hoffmann et al. [54] suggested that the Wnt pathway’s inhibition could promote the growth of HGSOC organoids. Beside, other growth factors and signaling molecules, including epidermal growth factor (EGF), noggin, R-spondin1, nicotinamide, and the Rho kinase inhibitor, Y-27632 are commonly used in EOC organoid cultures [51, 52]. On the whole, it appears from available literature data that experimental conditions for EOC organoids culture should be standardized by experts.

First published data illustrated organoid cultures obtained from few EOC patients [55, 56] and/or short-term HGSOC organoids [57]. However, in a recent article by Kopper and colleagues [53], a main development in EOC organoids was published. PDOs were obtained from non-malignant BOTs, as well as MOC, CCC, EnOC, LGSOC, and HGSOC with an overall success rate of 65%; notably, even after extended passaging, PDOs have been shown to morphologically and molecularly match the parent tumors from which they were derived [53]. In addition, organoids recapitulated EOC hallmarks, such as CNV, recurrent mutations, and tumour heterogeneity. Authors also obtained OSE- and FTE-derived organoids, and they used gene manipulation technologies (CRISPR/Cas9 Gene Editing) to assess the potential of these experimental models to study early HGSOC development. Likewise, Maru and colleagues [58] documented faithful duplication of histological features and tumour heterogeneity within PDOs derived from various subtypes, including HGSOC, MOC, and EnOC. Later publications have corroborated the potential of PDOs to be employed for drug screening, as well as for studying OC biology and mechanism of drug resistance [54, 59–63].

Overall, research findings support the use of PDOs as an attractive platform for modeling EOC, drug–response prediction/patient selection and for high-throughput drug screening. A longitudinal observational phase II, single-center, single arm study (NCT04555473) is now ongoing in our Institution to evaluate the reliability of HGSOC organoids obtained from primary debulking surgery (PDS) + adjuvant chemotherapy and neoadjuvant chemotherapy + interval debulking surgery (NACT + IDS) cases, as model for the patients’ response to treatments. We also aim to study the genomic and phenotypic evolution of tumour cells in HGSOC organoids from PDS + adjuvant chemotherapy and
NACT + IDS patients undergoing relapse. Other clinical trials are also ongoing worldwide to evaluate the role of PDOs in predicting the clinical efficacy of anticancer drugs in OC (NCT02732860, NCT04279509, NCT04768270, NCT05175326, and NCT05290961). Results from these trials will help defining the consistency of these models as avatars for human disease and their use in coclinical studies. Currently, collections of EOC PDO and matching healthy organoids are generated and biobanked to be employed for screening of new drugs or new drug combination.

However, the model has some important drawbacks: the process is time-consuming, with a high variability in the success rate and time of establishment, partly because of biopsy quality or size. Indeed, organoid development efficiency is strongly dependent on the viability of the cells after dissociation, in turn linked to primary patient characteristics, including tumour histotype, grade, and cell composition of the clinical specimen. Low tumour purity can also influence genomic correlation between PDO and tissue [53]. Mostly important, organoids are devoid of the native microenvironment, with a lack of vasculature, tumour stroma and immune cells, factors playing a critical role in translational cancer research. Therefore, drugs targeting tumour microenvironment, including anti-angiogenic and immunotherapeutic agents, cannot be tested in tumour-derived organoids [64]. Besides, it should be kept in mind that tumour microenvironment (TME) may alter drug response, determining discrepancies between drug sensitivity in vitro and in vivo [65]. The development of co-culture conditions of organoids with immune cells or other cells may overcome these limitations. Notably, Wan and colleagues [66] have recently generated short-term co-cultures containing tumour organoids and the full complement of intratumoral immune cells from 12 solid tumors of HGSOC patients to test a unique bispecific anti-PD-1/PD-L1 antibody compared with monospecific anti-tumors of HGSOC patients to test a unique bispecific anti-

**Tumour-on-a-chip**

Recently, tumour-on-a-chip systems have emerged as a powerful tool for studying tumour biology, metastatic pathways, and drug screening. These systems consist in a microfluidic device, obtained with advanced microfabrication techniques, where different cell types are seeded within separate chambers to recreate the dynamics found in the TME [67]. Typically, microfluidic models are obtained by seeding and culturing cells in 3D scaffolds in a small chamber, under perfusion of culture medium. The microfluidic perfusion permits an accurate control of microenvironment, and manipulation of physical and biological parameters. Importantly, the latest microfabrication techniques allow the integration with different component of TME as stroma and immune system cells. Specifically, Saha and colleagues [68] have developed an OvCa-chip in which A2780 cells or primary cells obtained from HGSOC patients were co-cultured with endothelial cells in two overlaid microfluidic chambers separated by matrix-coated porous membrane. To mimic platelet extravasation dynamics, the vascular lumen of the device was perfused with platelets, suggesting an active role of OC cells in this mechanism [68]. More recently, the same authors developed an ovarian tumour microenvironment chip (OTME-Chip) that, in addition to the tumours interfacing platelet-perfused vascular endothelial tissue, also incorporates an adjacent well-defined collagen hydrogel-based ECM microenvironment. This platform has been also integrated with gene editing and next-generation RNA sequencing (RNA-seq) tools to study vascular and hematological targets in OC [69]. Likewise, Surendran and colleagues [70] have developed a 3D tumour/neutrophils-on-a-chip device in which EOC spheroids produce an in vivo-like immune response associated with neutrophil chemotaxis. Overall, although tumour-on-a-chip allows to achieve valuable results for the EOC studies, some critical issues need to take into account regarding its applicability, including the complexity of design and use, the limited biomaterials choice, and the weak standardization using commercially available cell lines.

**Ex vivo models**

Ex vivo models are mostly represented by patient-derived explant (PDE) in which fresh surgically resected tumour can be cultured ex vivo (entirely or in slices, with or without a cellular matrix) for a period of time. These models potentially maintain the spatial conformation of the tissue, heterogeneity, and tumour grade, and therefore, they can successfully be used for studying cancer biology and developing personalized treatment. Over the time, different ex vivo culture methods have been developed by different research groups, with different tumors requiring different culture conditions. Briefly, explants may be maintained as fragments or processed for generation of tissue slices of around 300 μm and subsequently cultured as free-floating culture or using grid/pore membrane supports, or gelatin sponge supports [71]. Use of tissue slices facilitates drug diffusion, but may result in the loss of tissue architecture. Slicing methods reported for EOC tissues include manual dissection with a scalpel [72] and the mechanized sectioning systems Krumdieck [73–75] and McIlwain Tissue Chopper [76]. Manual slicing is becoming less common due to the lack of uniformity in explant thickness, while the Krumdieck tissue slicer is the most used in OC research, being considered adequate for the purpose of developing precision tissue slices for subsequent culture. Another instrument described for fresh tissue sectioning is the vibratome that, compared with other
Instruments available, has been suggested to better preserve the integrity of delicate samples, thus ensuring a higher number of viable cells on the section surface [77]. However, there appears to be little information on the use of this latter method in precision slicing of EOC, and therefore, further studies are needed to define the golden standard approach. For incubation conditions most studies use 37 °C, 5% CO₂ and 21% oxygen [71, 78]. Further details on culture conditions can be found in a focused review by Templeton et al. [78]. Tumor explants cultures can also be combined with adjacent healthy tissue or cell culture, as for example lymphocytes from peripheral blood mononuclear cells (PBMC).

Endpoint analysis for studies assessing drug response includes either enzymatic digestion followed by evaluation of cell viability or cytotoxicity using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay [as in the case of Histoculture drug response assay (HDRA) assay [79]] or the PDE can be left intact and processed for spatial biomarker analysis [78]. If the PDE is homogenized, protein and nucleic acids can be extracted and omics data generated.

Overall, limited literature data are available on patient-derived explants of EOC. Indeed, besides studies reported above, showing that the ex vivo explant assay is a robust and cost-effective model to assess chemosensitivity and the effect of novel therapeutics in EOC [71–76], a few more investigations have been carried out applying the HDRA assay to the prediction of drug response in EOC [80, 81]. Specifically, Nakada and colleagues [80], using a modified HDRA in a total of 164 patients, reported a high evaluability rate and a strong correlation with the clinical response. Similar results were reported later by Jung and colleagues [81] who, in a prospective clinical trial, found a significant association between the in vitro HDRA chemosensitivity to carboplatin and paclitaxel, and the PFS of patients with advanced EOC. Recently, however, the applicability of HDRA to predict platinum sensitivity and prognosis in EOC has been questioned by Lee and colleagues [82].

Interestingly, to improve the longevity and preserves the histopathological features of EOC explants, Abreu and colleagues [83] have recently developed a long-term agitation-based EOC-PDE culture platform that retains the tumour microenvironment and patient-specific features. According to author’s conclusion, this experimental model may allow to explore disease mechanisms, to test new drugs, and to elucidate drug response and resistance mechanisms, due to the feasibility of cyclic drug treatments.

The main drawbacks of these ex vivo methods are the limited accessibility of fresh tissues, the lack of reproducibility, due to the natural heterogeneity of donor tissues (or possibly due to the small amount of tissue that could not reflect the cancer heterogeneity), and the limited cell viability (of few days), as a possible consequence of limitation in the diffusion of nutrients and oxygen.

In vivo models

In EOC studies, three species are most commonly used, i.e., mouse, rat, and laying hen. The laying hen is distinctive in being the only model that allows observations of early events in disease progression, and indeed, it is suited for chemoprevention studies. On the other hand, rodent models represent the gold standard for tumour growth and tumour response to drug compounds, although limitations exist including ethical controversy, the species-specific differences between animals and humans, low-throughput drug optimization, and animal expenses. The most widely used rodent models in EOC research include xenograft, syngeneic, and genetically engineered models [84, 85].

For xenografts and/or syngeneic models, three important factors need to be taken into account in the context of EOC: (i) tumour cell source, i.e., established or primary cancer cell line, or surgical resections; (ii) location of transplanted tumour cells (orthotopic vs heterotopic); and (iii) immune status of the host (mouse immune system, immunocompromised or human immune system). The two major methods of engraftment are subcutaneous (SC) and intraperitoneal (IP) injections. After subcutaneous engraftment of cancerous cells or tissues, tumour formation is confined to the place of implantation and grows within weeks, showing histology similar to the original tumour. It can be readily quantified with calipers, rendering it a suitable model for studies of drug response. IP injection allows obtaining a disseminated cancer model, mimicking metastatic behavior of EOC. Cancer foci are quickly formed within the peritoneum, on the liver and spleen surface, similar to the advanced stages of human EOC. Only a suspension of established or patient-derived cancer cell lines can be injected via IP. In orthotopic mouse models, tumour cells are transplanted in the anatomical location from which they were originally derived, as ovarian bursae (IB, intrabursal) [85]. IB injections are technically challenging and require skill and experience, possibly resulting in low implantation rate and tumour size variability among mice. Besides, the anatomical difference between mouse and human ovaries (the bursal membrane is a unique feature in mice) may affect the ability of cancer cells to leave the primary site of injection in IB models. Importantly, the orthotrophic model has similar TME as the original tumour and therefore more closely resemble the tumorigenesis in patients, in terms of vasculature, gene expression, response to chemotherapy, and metastatic biology [86]. Orthotopic implantation or IP injection of EOC cells are thus more clinically relevant, but more complex when analyzing changes in tumour growth. This can be monitored by different methodology including magnetic resonance imaging (MRI), ultrasound (US), and bioluminescence imaging.
MRI and US are used to determine volumes and internal structure of the tumours, monitoring the tumour growth and metastasis [87]. However, these approaches in preclinical studies are extremely expensive and time-consuming, especially with a large number of mice. Using EOC cell lines stably transfected with a luciferase-expressing gene, the tumour burden, including metastasis, can be analyzed by measuring bioluminescence emission using In Vivo Imaging System (IVIS) [88]. This approach is much simpler and economical, but cannot be applied to engraftment with tumour tissues. Overall, the inherent difficulties in monitoring IP or IB disease formation and progression (unless specific equipment for the in vivo imaging system are available) may increase the risk of the animals’ distress [89]. Consequently, the choice of appropriate humane endpoints is more difficult in these models, an issue that can be questioned by the Ethical Committees for animal experimentation. In conclusion, taking into accounts all these aspects, the use of SC xenografts may be considered at the early stages of in vivo preclinical evaluation of a new drug. If encouraging results are achieved, they have to be confirmed in mid- to late-stage research in more clinically relevant models.

Features relative to tumour cell source and immune status of the host are described below.

**Carcinogen-induced tumour models**

Numerous studies have reported the use of 7,12-dimethylbenz[a]anthracene (DMBA) to induce ovarian tumors in rodents, mainly in rats, by exposing ovaries to the carcinogen either by introduction of a DMBA-saturated suture/gauze under the ovarian surface, or by injection of DMBA directly into the ovary [90–95]. Importantly, however, the animal strain used, the age of the animals, or the use of concomitant hormone treatment was shown to significantly affect the rate of tumour formation as well as the histologic types of experimental ovarian tumours, with a variable histologic distribution, including both epithelial and sex-cord stromal tumours. Thus, although these models have the advantages of encompassing all stages of the neoplasia, the lack of standardization has actually limited their use.

**Syngeneic models**

In syngeneic models, also known as allograft models, tumour cells (or tumour tissues) derived from a particular inbred strain are engrafted into hosts of the same strain. These models allow studying the interaction between the tumour and the immune system, as well as the effects of immunotherapies on tumour and surrounding immune cells.

Currently used models for EOC include the commonly used ID8 murine model [96] together with genetically modified versions of these cells [97–101]. The syngeneic mouse model permits EOC initiation directly from mouse OSE (MOSE). MOSE cells scraped from the mouse bursa were passaged in culture on plastic until phenotypic changes occurred, such as the loss of cell contact inhibition, which resulted in cellular mounds and changes in cell morphology [96]. Late passage MOSE (clone ID8) cells injected IP into syngeneic C57BL/6 mice gave rise to peritoneal tumours with ascites, within about 90 days; tumour formation following SC injection occurred in ~4 months [96]. Later, Greenaway and colleagues [102] demonstrated that orthotopic grafting of ID8 cells into C57BL/6 mice could induce, between 80 and 90 days post-injection, the formation of epithelial ovarian tumours and secondary lesions throughout the peritoneal cavity, with cytological and architectural features resembling serous carcinoma; extensive abdominal ascites was recorded, as well.

Nonetheless, genomic analysis has shown that ID8 tumours do not carry the common mutations and somatic copy-number alterations observed in human HGSOCs, such as those occurring in *Trp53, Brca1*, and *Brca2* [99]. Using CRISPR/Cas9 gene editing, Walton and colleagues generated sublines of ID8 that recapitulate critical mutations in human HGSOC, as single (*Trp53*–/–) or double mutants, with deletions in *Brca1, Brca2, Pten* and *Nf1* in addition to loss *Trp53*, as well as triple mutants lacking *Trp53, Brca2* and *Pten* [99, 100]. Collectively, their results indicate that these cell lines can represent powerful models to clarify HGSOC biology and chemotherapy resistance, demonstrating that tumours derived from differing mutations respond differently to treatments and result in alterations in immune cell infiltration into the tumour microenvironment. More recently, Iyer and colleagues [103] engineered a panel of murine fallopian tube epithelial cells bearing mutations typical of HGSOC and capable of forming tumours in syngeneic immunocompetent host. Interestingly, the models were set up to reproduce molecular pathway occurring in homologous recombination (HR)-deficient or HR-proficient patient population and their clinical relevance was further corroborated by their responsiveness to both DNA-damaging agents and PARP inhibitors. These experimental systems could be particularly important to address the clinical unmet need of alternative therapeutic options for patients with HR-proficient HGSOC. Besides, they might identify predictive biomarkers to improve women response rates under treatment, particularly in the field of immunotherapy.

**Xenografts of established ovarian cancer cell lines**

Xenograft models have been largely used in EOC research and are still very important for preclinical drug screening.
Preclinical models of epithelial ovarian cancer: practical considerations and challenges...

These models require use of immunodeficient mice strains that show a decreased immunological response. Several strains are available: the athymic nude mouse lacking T lymphocytes (Foxn1 Nu/Nu, with spontaneous deletion in forkhead box N1 gene); the severe combined immunodeficiency (SCID), depleted of functional B and T lymphocytes; the non-obese diabetic (NOD)/SCID and the NOD/SCID/IL2Rγ null mice (NSG) deficient in mature lymphocytes and NK cells [104]. Established cell lines have been generally used for xenotransplantation experiments, showing variable ability to grow in nude mice when implanted SC, IP, or IB. The rate of engraftment of human OC cell line can be improved by mixing them with Matrigel [105].

Overall, available data suggest that some cell lines are tumorigenic in both SC and IP locations, while others exhibit a strong propensity to grow in one site only, this implying that the TME can reprogram different signaling pathways for tumour proliferation. Shaw and colleagues [106] evaluated tumour formation after IP injection of 11 EOC cell lines (HEY, OVCA429, OVCA433, OCC1, OVCAR-3, SKOV-3, A2780-s, A2780-cp, OV2008, C13* and ES-2) in nude mice to characterize their growth patterns and disease histology. ES-2, OCC1, A2780-cp, and HEY were the most aggressive cell lines (median survival time < 30 days), while A2780-s, OVCA429, OV2008, and SKOV-3 were less aggressive (median survival time 2–3 months). Conversely, C13*, OVCA433, and OVCAR-3 cells failed to form IP tumours within 3 months. Histologically, A2780-s, A2780-cp, ES-2, HEY, and OCC1 were defined as undifferentiated carcinoma; OVCA429 and SKOV-3, as CCC; and OV-2008 and C13* as EnOC with foci of squamous differentiation [106].

Besides, comparison of tumour characteristic between IP and IB dosing showed that for both OVCA429 and ES-2, the site of injection did not affect the tumour histology, while the tumour take rate was negatively affected for OVCA429 cells [106]. Later, Mitra and colleagues [107] compared growth characteristics of IP and SC injection of different EOC cell lines (CAOV-3, COV362, KURAMOCHI, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, OVSAHO, OVKATE, SNU119, and UWB1.289) in female athymic nude mice. Each cell line displayed different growth characteristics in vivo. OVCAR-3 cells formed rapidly IP tumours with HGSO histology, while OVKATE and COV362 formed only tumours by SC injection. Only OVCAR-8 formed ascites. Three cell lines (KURAMOCHI, SNU119, and UWB1.289) were non-tumorigenic. Likewise, also Hernandez and colleagues [108] evaluated in vivo tumorigenicity of a panel of EOC cells after SC, IP, or IB injection. They demonstrated that A2780, OVCAR-5, OVCAR-8, IGROV-1, SKOV-3, CAOV-4, PEO1, and MDAH-2774 were medium/highly tumorigenic via SC injection; with the exception of IGROV-1 and PEO1, the same cell lines also showed a medium/high ability to form tumours when injected IP; authors also reported that only OV-90, OVCAR-8, and CAOV-4 were highly tumorigenic in IB location. Notably, they showed that cell lines showing preference for IP growth had gene expression patterns more similar to primary tumours, although, histologically, the IP tumours appeared as undifferentiated carcinoma, without clear morphology of any human histologic subtype [108].

In our experience, PEO1 or COV318 cells did not form tumours in athymic nude mice injected either via IP or SC (unpublished data); on the other hand, A2780, OVCAR-3, SKOV-3, and HEY cells were tumorigenic after SC and IP injections [47, 109–111].

Established EOC cell lines in vivo have some advantages including fast tumour growth and intra- and inter-laboratory reproducibility. However, even if these models are particularly useful for drug screening, the immunodeficiency state does not allow to evaluate the contributions of the immune factors to tumour development. Besides, it is important to confirm cancer cell line identity, before injection into mice. Likewise, the histological subtype of tumour grown in mice needs to be evaluated by immunohistochemical and, possibly, mutational analysis.

Patient-derived xenografts (PDX)

Patient-derived xenografts (PDXs) are generated by direct SC, IP, or orthotopic engraftment of clinical samples into immunodeficient mice; after the tumour reaches a critical size, it can be excised and implanted into subsequent mice. Surgically resected tumours, patient-derived cells, or samples from ascites can be used to produce ovarian cancer PDXs. There are advantages and disadvantages in utilizing either tumour fragments or single-cell suspensions. Indeed, tumour fragments maintain cell–cell interactions and the architecture of the original tumour, mimicking its microenvironment; on the other hand, the cell isolation procedures improve cell viability and engraftment success, although, during cell passaging, the population can enrich for subclones. Under the different experimental conditions, a wide variation occurs in the percentages of engraftment and time to develop tumours. With regard to the IB and IP route, available data reveal high engraftment rate (> 70%), particularly when SCID or NOD-SCID-IL2γR mice are used [112–115]. Weroha and colleagues [114] described the first large bank of EOC PDX, obtained after IP injection of tumour slurry in SCID mice. They reported an engraftment rate of about 70% (168/241), with microscopic fidelity and comparable genomic aberrations with the corresponding primary tumour. Notably, serous tumours displayed a higher PDX rate compared to other histotypes. They also demonstrated that responses to carboplatin and paclitaxel in vivo correlated well with the corresponding patient’s clinical response [114]. Similar findings were described...
by George and colleagues [115], developing over 40 PDX models using an orthotopic transplant approach in NSG mice with a 93% success rate \((n = 37\) of 40, time to take rate within 4 to 6 weeks of transplant) and 100% take rate for F1 and F2 generations. Interestingly, they also generated 14 orthotopic HGSOC PDX models with BRCA1/2 mutations (BRCA MUT) [115]. However, lower take rates were reported by other groups, although with some differences in experimental conditions. In detail, Ricci and colleagues [116] xenotransplanted in nude mice 138 tumour samples by SC, IP, or IB injection, achieving a 25% tumour take rate after IP injection was reported by Dobbin of initial implantation varied from 2 to 12 months. An even development of clinically apparent disease from the time 29 PDX, for a take rate of 31% \((29/94)\). The latency time to growth through at least three serial passages, they established fluid of patients: considering PDX models that successfully generated PDX models in irradiated nude mice from IP injections of tumour cells isolated from the ascites or pleural fluid of patients: considering PDX models that successfully grew through at least three serial passages, they established 29 PDX, for a take rate of 31% \((29/94)\). The latency time to development of clinically apparent disease from the time of initial implantation varied from 2 to 12 months. An even lower take rate after IP injection was reported by Dobbin and colleagues [118], who compared the take rate of different sites of transplantation, i.e., SC, IP, MFP (mammary fat pad), and SRC (subrenal capsule) in SCID mice. Specifically, they found a 22.2% take rate after IP injection, while obtaining higher values after MFP or SC xenotransplantation \((63.64\% \text{ and } 85.3\%, \text{ respectively})\). The lowest take rate was found for SRC implantation, i.e., 8.3% [118]. Conversely, Stewart and colleagues [119] reported that the injection of CD45-depleted serous OC cells (obtained from HGSOC patients) via IP, SRC, IB, or MFP route in NOD/SCID mice resulted in high tumour takes regardless of the transplantation route (\(>70\%\)). A limited number of studies have been carried out using the SRC route for tumour xenotransplantation. Besides those reported above [118, 119], also Lee and colleagues [120] reported a high rate of different histotype of EOC in SCID mice via the SRC route in a limited case series. Finally, Heo and colleagues [121] developed PDXs by SRC implantation of primary EOC tissues into female BALB/c-nude mice, with a rate of successful PDX engrafment of 48.8% \((22/45 \text{ cases})\) and showed that patients whose tumours successfully engrafmented in mice had inferior OS.

With regard to the SC route, Eoh and colleagues [122] successfully engrafmented 49 out of 88 EOC specimens \((53.4\%)\) in NOG \((\text{NOD/Shi-scid/IL-2Rynull})\) mice, suggesting that engrafment failure of chemotherapy-naïve tumors reflected low aggressiveness of the primary tumour. Likewise, Cybula and colleagues [123] associated the successful tumour engrafment rate to intrinsic features of the primary tumour reflecting its aggressiveness. Using NOD/SCID, NSG, or NRG \((\text{a strain very similar to NSG})\), they established a panel of HGSOC PDXs, by SC transplantation with an overall take rate of 77% \((33/43)\) and a latency time from 4 to 10 months. They found no differences in tumour take rates between NSG and NRG mice, while slightly less in NOD/SCID mice. However, only 17 out of the 33 PDX engrafmented could be further expanded through multiple rounds of serial transplantation [123].

It appears from the studies examined that a better engrafment rate can be achieved by implanting tumour tissues into SCID or NOD-SCID-IL2R mouse, rather than BALB/c nude mice. However, despite the more immune-compromised strains appear to have higher take rates, establishing PDX tumour models in NSG mice has presented some challenges and limitations. Indeed, several recent studies have revealed that OC PDX engrafmented in NSG and NOG mice are susceptible to Epstein–Barr virus (EBV)-associated lymphomagenesis. Butler and colleagues [124] observed a lymphoma rate of about 11% in a panel of 117 EOC PDX. In line with these findings, preliminary data from our lab also show that a not negligible proportion of PDXs turn out to be human lymphocytic tumours (unpublished data). These lymphoproliferative lesions were consistently characterized by atypical growth kinetics with fast tumour growth generating soft, flat tumour masses. Evidence of lymphoproliferative tumours development after transplantation of OC PDX was also reported by Cybula and colleagues [123]. Notably however, in contrast to others, this study did not detect EBV-associated, but mouse lymphomas.

An important aspect to take into account is the molecular fidelity of PDX models to original human tumour. On the whole, available literature data comparing small numbers of PDX models and human tumors at the molecular level suggest that PDX models of EOC largely maintain molecular features of the original tumour [114–118]. Izumchenko and colleagues [125] also showed that the background mutation frequencies in EOC PDXs and primary TCGA tumors were highly comparable. However, some degree of genomic variation has been reported. Liu et al. [126] compared the gene expression profile of paired PDX and donor tumors, evidencing differences mainly related to the loss of human stroma in PDX tissues or reflecting changes required for a human tumour to adapt to a murine host [126]. Besides, despite an overall similarity, some degree of genetic evolution is expected in higher-passage PDX tumors and/or at the time of PDX initiation and adaptation to mouse host, due to clonal selection and/or clonal evolution [123, 127]. Chen and colleagues [128] also explored a relevant cohort of EOC patients and reported that PDX models generated in the study retained the protein expression, and genetic alteration patterns of the original tumors. Notably, despite the transcriptomic differences observed, the PDX models demonstrated a high degree of similarity with patients in terms of the chemotherapy response, indicating that non-driving
differentially expressed genes (DEGs) not affected drug sensitivity.

It is also apparent from a number of the above-mentioned studies that a very good correlation exists between patient drug response and PDX response to the same drug [114–118, 125, 128]. In this respect, coclinical trials with PDX models have been initially proposed to form mouse-avatars models for conducting personalized treatment testing for the patient from whom the PDX was derived. However, the relatively long time required to complete in vivo studies has suggested that the possibility to use PDX response data to drive individual patient’s treatment is hardly achievable at this time. We searched on ClinicalTrials.gov for clinical trials on PDX/EOC (27 April 27 2022) and identified a total of three relevant studies, two completed from Mayo Clinic (NCT02283658 and NCT02657928) and one recruiting from Princess Margaret Cancer Centre Toronto (NCT02732860). For the two completed trials, the development of PDX avatars on tumors from participants was a tertiary objective. Both studies confirmed the feasibility of PDX from the majority of patients, but authors concluded that PDX coclinical trial attempting to use PDX response data to impact an individual patient’s treatment would be challenging, due to the evidence that time required to create a PDX commonly exceeded the patients’ time on study [129, 130].

For the ongoing trial (NCT02732860), the evaluation of the utility of PDX (comprehensively characterized by genomic and epigenetic analysis) as clinical predictors to direct the use of chemo- and targeted therapies in patients with different cancers, including HGSOC, is the primary outcome. Interestingly this trial also explores organoids to correlate between PDX and organoid drug sensitivities. Results of this study will provide further insights into critical aspects of the PDX models, as those related to their faithful representation of the original tumour and their genomic stability.

Different providers offer PDX models of EOC, although they are often quite expensive. In addition, research companies may require researchers to outsource the study to the company or do not authorize researchers to passage and expand the PDX tissue in mice independently. In 2013, several European and US Institutions started the EurOPDX consortium (https://www.europdx.eu/), with the goal of building large collections of models to cover cancer heterogeneity and to raise standards in the preclinical setting. The consortium has collected until now (accessed on 9 February 2022) more than 1500 SC and orthotopic PDX models, including 142 OC. Models are accessible for transfer to academic laboratories on a collaborative basis; from October 2018, part of the collection is available for free-of-charge Transnational Access (TA) through the EurOPDX Research Infrastructure.

Interestingly, the Jackson Laboratory and the European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI) have implemented PDX Finder, a comprehensive open global catalogue of PDX models and their associated datasets (http://www.pdxfinder.org). PDX Finder currently delivers access to information for 4542 PDX models (about 90 EOC, accessed on 11 March 2022) in eight repositories around the world, including NCI’s Patient Derived Model Repository, The Jackson Laboratory’s PDX Resource, members of the EurOPDX Consortium and members of NCI’s PDXNet [131]. Clickable links will allow users to contact the relevant institution for further collaboration/model acquisition.

Overall, PDX model represents an interesting platform for the identification of predictive biomarkers of response as well as for testing the efficacy of new drugs or new therapeutic strategies. PDXs are also valuable tools for generating drug-resistant tumour models and investigate the molecular basis for this resistance.

### Humanized mouse models

Humanized mouse models are generated by the engraftment of human cancer cell line-derived xenografts (CDXs) or patient-derived xenografts (PDXs) into immunodeficient mice harboring also human immune cells. Different models are commonly used in human oncology studies, with each models having their own strengths and limitations; these different experimental approaches have been reviewed in detail in several previous reports [132]. Humanized mice model platforms are available from different companies and include (a) humanized CD34 + (huCD34) mouse models, ideal for long-term oncology studies as they involve stable engraftment of huCD34 + hematopoietic stem cells (HSC), and produce multi-lineage human immune cells; (b) humanized PBMC (huPBMC, human peripheral blood mononuclear cell) mouse models, ideal for short-term tumour studies evaluating compounds for T-cell immune modulation; (c) knock-in humanized mouse models, including humanized CTLA-4 or PD-1 models, to evaluate the anti-tumour response of immune checkpoint inhibitors directed to human targets in preclinical syngeneic tumour models with a fully functional immune system.

A derivative of the NSG mouse, called NSG-SGM3 (NSGS), is commercially available and may be a useful model for EOC research [133]. This triple transgenic model displays the features of the highly immunodeficient NSG mouse in combination with the expression of human IL-3, GM-CSF (granulocyte macrophage colony-stimulating factor, CSF2) and SCF (stem cell factor, KITLG). When engrafted with CD34 + human hematopoietic progenitor cells, the NSG-SGM3 mice display increased haematopoietic stem cells, B cells, CD34 + myeloid cells, CD3 + T cells, CD4 + T helper cells, and CD8 + T cytotoxic cells. This validated platform support robust tumour growth and can be used for efficacy testing of novel immunotherapies targeting...
T cells and myeloid cells. This is particularly interesting when considering that the immunosuppressive myeloid cells TAM represent the most abundant host cell population within tumour stroma in EOC and have been shown to drive cancer cells toward a chemoresistant phenotype [48, 134].

In the context of EOC research, Bankert and colleagues [135] published results from an interesting study reporting a simple and reproducible system in which the tumour and tumour stroma were successfully engrafted by injecting tumour cell aggregates derived from fresh ovarian tumour biopsies (including tumour cells, and tumour-associated lymphocytes and fibroblasts), IP into NSG mice. The tumour-derived cell suspensions (from the fresh solid tumour tissue disruption) contained CD45 + leukocytes, cytokeratin-positive cells, and trichrome-positive collagen, which is produced by fibroblasts. This model that recapitulates tumour progression, ascites formation and metastasis as observed in patients, was utilized to evaluate human IL-12 loaded liposomes as a potential immunotherapy for EOC. Later, Chang and colleagues [136] using a humanized mouse model demonstrated that anti-CCR4 monoclonal antibody could restore anti-OC immunity through modulation of Treg activity. More recently, Gatto and colleagues [137] validated an autologous humanized tumour-infiltrating lymphocytes (TIL)/PDX platform for assessing patient-specific T-cell response to immunotherapy and testing immune modulating agents and combination strategies in vivo. The autologous model platform, as that proposed by Gatto et al. [137], has a high translational value, although it is particularly challenging, since the development of each model depends upon the availability of patient tumour tissue and effective TIL expansion.

**GEMMs**

Genetically engineered mouse models (GEMMs) of EOC represent excellent preclinical models for studying disease prevention, early detection, and therapy, and have been developed to resemble different molecular phenotypes and histotypes [138, 139]. Certainly, the most effort has gone into the development of GEMMs for HGSOC (reviewed in detail in [138]), although controversies about its cellular origin [140] have made difficult to establish robust models. Now, it is increasingly accepted that both the FTE and the OSE can give rise to HGSOC [19, 20], even if by introducing the same genetic alterations in OSE or FTE, Zhang and colleagues [20] demonstrated that the resulting tumors differed in inter-tumour heterogeneity, molecular pathogenesis, biology, and drug response. The development of HGSOC GEMMs, fully recapitulating early alterations and disease progression seen in patients, still represents an important issue.

Connolly and colleagues [141] at Fox Chase Cancer were among the first who developed a spontaneous transgenic mouse model of EOC by expressing the oncogenic early region of SV40 under the transcriptional control of the Mullerian inhibiting substance type II receptor gene promoter (MISIIIR). SV40 Tag binds to and functionally inactivates p53 and Rb [142], which are frequently mutated in human ovarian cancer [143]. Transgenic mice developed, in approximately 50% of cases, bilateral poorly differentiated carcinomas with metastases and ascites; cell lines derived from the ascites (MOVCAR) exhibited the features of EOC and were tumorigenic in immunocompromised mice [141]. Subsequently, to bypass early onset of OC and the lack of fertility, they generated a stable transgenic line of mice, TgMISIIIR-Tag-DR26, from an affected male transgenic founder (DR26). In this model, female offspring developed bilateral ovarian carcinomas with 100% penetrance, exhibiting morphology/rapid growth rate similar to human high-grade serous OCs [144]. Notably, these are the only GEMMs that develop spontaneous tumour with pathological features of serous EOC [141, 144]. Finally, the same group isolated individual transgenic lines of non-tumour prone C57BL/6 TgMISIIIR-Tag transgenic mice to be used as syngeneic immunocompetent hosts for allografted Tag expressing MOVCAR cells, isolated from tumour bearing C57BL/6 TgMISIIIR-Tag-DR26 mice [145]. Orthotopic/IP implantation of MOVCAR cells in TgMISIIIR-Tag-Low mice resulted in the development of disseminated peritoneal tumors, resembling to human HGSO [145].

Later, EOC GEMMs have been developed using specific promoters (e.g., Pax8 and Ovgpl) to drive the inducible expression of Cre-mediated recombination of floxed target alleles in OSE or FTE of engineered mice. This Cre-loxP system allows the conditional knock-in and knock-out of tumour suppressor and/or oncogenes, such as Trp53, Rb1, Myc, Akt, Pik3ca, Pten, and Arid1a, considered the major driver genes promoting cancer progression in different EOC. To achieve a spatio-temporal genetic alterations, in some GEMMs, the specific promoter controls the expression of Cre recombinase regulated by tamoxifen or tetracycline [146–148].

Alternatively, a replication-deficient adenovirus altered to express Cre under the control of the CMV promoter (AdCre) has been delivered directly into the space between the ovary and the ovarian bursal membrane to mediate inactivation of floxed genes in engineered mice [149]. Although this approach allowed overcoming the difficulties of identifying specific promoters, it presents some limitations including technical problems associated with IB injection of the adenovirus encoding Cre recombinase. The AdCre based-models show a lower penetrance when compared to promoter-driven models.
Although the benefit of using GEMMs, their establishment requires extensive and time-consuming breeding programs. With the advances in gene editing technologies, such as CRISPR/Cas9, new and much more rapid GEMMs have been developed at a significantly lower cost compared with traditional breeding protocols. Recently, two different studies [150, 151] reported a novel strategy to generate somatic EOC mouse models using a combination of in vivo electroporation (EPO) and CRISPR-Cas9-mediated genome editing. Different combination of tumour suppressor/oncogenes (i.e., Brcal, Trp53, Pten, Lkb1, Rb, and Myc) resulted in successfully generation of HGSOc, showing to be a high flexible and powerful tool. Table 1 summarizes some models developed for different EOC subtypes [152–162]. Notably, the altered genes are important to determine GEMMs histotypes, independently of the method used (i.e., driven-promoter, adenovirus, and electroporation).

Overall, GEMMs allow studying tumour initiation and progression as well as exploring novel therapeutic strategies in immunocompetent and genetically defined mice. Major problems linked to GEMMs are their complex breeding programs and, more importantly, their mixed backgrounds which precludes the development of tumour cell lines that can be used for syngeneic studies, ultimately making them unsuitable for studies of tumour immunity and immunotherapy [146, 148, 157]. Therefore, a syngeneic transplantable model with appropriate mutations would represent a more reliable model. As already stated before, the most frequently used murine cell line ID8 does not retain the typical mutations and copy-number alterations that define human HGSOc. Besides the genetic engineering of the ID8 model discussed above [99], an interesting approach has been proposed by Maniati and colleagues [163] who recently characterized the TME of six orthotopic, transplantable syngeneic murine HGSOc lines established from GEMMs backcrossed onto B6 background [146] and GEMMs generated by adeno-virus transduction [159]. Interestingly, they showed that many of the biomechanical, cellular, and molecular features of human HGSOc were reproduced in the murine tumors, with significant correlations in mRNA expression profiles, innate and adaptive immune responses, tissue modulus, and matrisome components [163].

## Laying hen model

The only non-human animal that spontaneously develops ovarian cancer with a high prevalence is the laying hen (Gallus domesticus). Tumors developed by laying hen are

| Table 1 | Selection of GEMMs developed for epithelial ovarian cancer research |
|---------|---------------------------------------------------------------|
| Cancer histology | Altered genes | GEMMs’ strategy | References |
| OC | Trp53;c-Myc;K-ras;Akt | RCAS | Orsulic et al. [152] |
| EOC | Trp53;Rbi | AdCre | Flesken-Nikitin et al. [149] |
| SOC | Trp53;Brcal;c-Myc | RCAS/Cre | Xing and Orsulic [154] |
| SOC | Pten;Pik3ca | AdCre | Kinross et al. [158] |
| LGSOC | Pten;Kras | Cre driven by Amhr2 promoter | Mullany et al. [156] |
| MOC; LGSOC; SOC | Pten;Kras;Trp53 | Cre driven by Amhr2 promoter | Ren et al. [161] |
| HGSOc | Dicer1;Pten | Cre driven by Amhr2 promoter | Kim et al. [157] |
| HGSOc | Trp53;Rbi;Brcal;Brcal2;Pten | AdCre | Szabova et al. [159] |
| HGSOc | Trp53;Brcal;Rbi1;Nf1;Pten | Cre driven by Pax8-Tet promoter | Perets et al. [146] |
| HGSOc | Trp53;Rbi | Cre driven by Ovgp1-TAM promoter | Zhai et al. [148] |
| HGSOc | Trp53;Rbi1 | AdCre | Zhang et al. [20] |
| HGSOc | Brcal;Trp53;Pten;Lkb1 | CRISPR-Cas9 Electroporation | Teng et al. [150] |
| HGSOc | Trp53;Pten;Rbi1;Myc | CRISPR-Cas9 Electroporation | Paffenholz et al. [151] |
| EnOC | Pten;K-ras | AdCre | Dinulescu et al. [153] |
| EnOC | Apc;Pten | AdCre | Wu et al. [147] |
| EnOC | Pten;Arid1a | AdCre | Guan et al. [160] |
| EnOC | Arid1a;Pten;Apc | AdCre | Zhai et al. [162] |
| EnOC | Apc;Pten | Cre driven by Ovgp1-TAM promoter | Wu et al. [147] |

Note: Different gene combinations have been tested. GEMMs genetically engineered mouse models, HGSOc high-grade serous ovarian carcinoma, LGSOc low-grade serous ovarian carcinoma, MOC mucinous ovarian carcinoma, SOC serous ovarian carcinoma, EnOC endometrioid ovarian cancer, EOC epithelial ovarian carcinoma, OC ovarian carcinoma, RCAS Replication-Competent ASLV long terminal repeat (LTR) with a Splice acceptor, AdCre replication-deficient adenovirus altered to express Cre under the control of the CMV promoter, AMHR2 Anti-Mullerian Hormone Receptor Type 2, CRISPR/Cas9 clustered regularly interspaced short palindromic repeats (CRISPR-associated protein 9, Ovgp1 Oviductal Glycoprotein 1, Pax8 Paired box gene 8, TAM tamoxifen, TET tetracycline
remarkably similar to human disease with an incidence tenfold higher than in women [164]. Barua and colleagues have reported that histological types as well as stages of EOC in hens are similar to humans [165]. Likewise, the risk of EOC development is highly correlated with age and number of ovulation [164]. Therefore, this model provides the opportunity to study risk factors for EOC as well as tumour initiation, progression, histological origin, and therapy response. In addition, it represents a valuable tool for preclinical testing of cancer therapy. However, the cellular origin of EOC in hens is controversial as observed in humans, being both the ovary and the oviduct involved at the time of cancer diagnosis. Recently, Paris and colleagues have developed a preclinical model of spontaneous EOC, particularly HGSOC, originated from oviductal fimbria [166]. This study, not only highlighted the similarities in term of histology and molecular markers between malignancies developed in hens and women, but, most importantly, offered the possibility to study different aspects of spontaneous HGSOC in women, including its early detection [166].

Overall, despite anatomical and physiological differences, the laying hen model offers benefits compared to murine xenograft models and GEMMs regarding the etiology and pathogenesis of EOC.

**Zebrafish model**

In recent years, the zebrafish (Danio rerio) has emerged as an attractive alternative to mouse in cancer research representing an efficient platform for investigating cancer and cancer therapeutics. The strengths of this model are the high fecundity, rapid external development, as well as easy, low-cost maintenance [167, 168]. Both embryos and adult zebrafish can be used for drug screening, although for embryos, the drug administration in their water is easier. About 70% of human genes have at least one zebrafish orthologue, and therefore, zebrafish cancer models, similar to human cancer, can be easily produced manipulating zebrafish genetics [169]. To overcome some drawbacks related to the genetically engineered models, as difficulties in controlling each step of disease, the technique of cancer cell transplantation into zebrafish embryos and adults has been used (reviewed in [170]). Among the advantages for using a zebrafish xenograft models, Kirchberger counts the lack of functional adaptive immune system in zebrafish larvae within the first 4 weeks after fertilization that prevents rejection of xenografts [170].

Moreover, zebrafish embryos and the adult Casper zebrafish line are excellent model organisms to image tumour development, metastasis, and microenvironmental interactions due to their optical transparency [167]. Using EOC cell line-bearing zebrafish embryos, zebrafish xenotransplantation models have been developed for assessing cancer progression or testing anticancer compounds [171, 172]. In more detail, Latifi and colleagues have injected OVCA433 cells [either untreated or treated with cisplatin or cisplatin + U0126 (a highly selective MEK1 and MEK2 inhibitor)], in zebrafish embryos to evaluate cell migration after 48 h [171]. Later, Wang and colleagues [172] used the same model to evaluate proliferation and metastasis of A2780 cells treated with different compounds. These studies suggest that zebrafish can be considered a valuable preclinical model of EOC complementing long-term mouse models. Interestingly, PDX using zebrafish as “avatar” for developing precision medicine strategies have been recently carried out both for patient tumour cells and tissues. However, these latter models are currently under development in EOC [173]. Importantly, some weaknesses limit the use of zebrafish for cancer research. First, the presence of an underdeveloped adaptive immune system in larvae is, on one side, a benefit in term of no rejection of xenografts but, on the other side, an obstacle for studying fully functional TME. Besides, physiological conditions are different between zebrafish and human, and especially, the temperature represents a critical factor (as reviewed in [174]).

**Conclusions**

Development of experimental models for EOC research presents significant scientific challenges. Essentially, it remains extremely difficult identifying high-quality tools with which recapitulate the molecular mechanisms underpinning the pathophysiology and the therapy-resistant recurrent disease to which patients ultimate succumb.

Established cell lines have been a fundamentally discovery tool in EOC, although an important matter that previous research has brought to light is that the most highly used cell lines are actually not representative of HGSOC, the most prevalent EOC subtype. Therefore, appropriate choice of cell lines for the different histotypes of EOC along with routine analysis of cell line authenticity are the first steps to increase the translational value of cell line studies in preclinical research on EOC. Besides, our and literature data have also demonstrated that established EOC cell lines, although easier to work with than primary cells, may not be recommended to understand determinants of sensitivity to current therapies or to translate novel therapies into the clinics [6, 175]. These models, however, under the right conditions and with the appropriate controls, retain their utility in mechanistic work at the protein and pathway level (Fig. 2).

On the other hand, primary tumour cell cultures more closely resemble the patient situation, and therefore, they represent a more experimentally accurate model for the reproduction of cancer in in vitro systems. Due to these unique features, they are a valuable experimental tool during

 Springer
Preclinical studies of drug resistance mechanisms, as we also recently demonstrated [175]. However, the need of characterization for determining origin and purity, the limited lifespan of days or weeks, and the slow growth, constitute important limitations to their use (Fig. 2).

Irrespective of their origin, 2D cell cultures cannot faithfully reproduce the real tumour microenvironment. Three-dimensional cell cultures, mirroring the physical and biochemical features of a solid tumour mass, show promise to bridge the gap between traditional 2D cell culture and in vivo animal models. Indeed, various studies have demonstrated that cancer cell lines grown in 2D and 3D culture often exhibit different gene/protein expression profiles, being the 3D system profiles more similar to those of the original cancer tissue [43]. Importantly, 3D cell culture has become one of the top methods of choice in drug discovery, being also better predictors of in vivo drug responses [59] (Fig. 2).

The biological translation of these in vitro systems is limited by the lack of the tumour-associated microenvironment, and therefore, they are not entirely suitable to capture the integrated biological properties of the native tumour. Approaches to model the ovarian TME, including co-culture with different cell types, such as immune cells, endothelial cells, and stromal cells, allowing a closer reproduction of the in vivo conditions, may offer major opportunities to improve translatability. In this context, the emerging tumour-on-a-chip platforms, integrating 3D cell culture, microfluidic technology, and tissue engineering hold great potential for being exploited as an alternative to in vivo animal studies, possibly accomplishing the international priority of the 3R principles, for Replacement, Reduction, and Refinement of animals in research (Fig. 2).

The above discussed models suffer from the drawback of not contextually preserving human tumour architecture. By contrast, ex vivo models, including tissue slices

---

**DISTINCTIVE FEATURES OF IN VITRO/EX VIVO PRECLINICAL MODELS**

| Advantages | Disadvantages |
|------------|--------------|
| • Ease of propagation | • Need periodic authentication by DNA profiling |
| • Useful for mechanistic insights | • Selection of clones (high passage number/long duration culture conditions) |
| • Low cost | • Not useful for identification of mechanisms of drug-resistance |

| Advantages | Disadvantages |
|------------|--------------|
| • Molecular features similar to original tumor | • Need purification and characterization |
| • Resemble patient heterogeneity | • Slow growth |
| • Resemble response to chemotherapy | • Limited lifespan |

| Advantages | Disadvantages |
|------------|--------------|
| • Reproduce cell aggregates in ascites | • Lack of TME |
| • Suitable for drug screening | • Not all cell lines form spheroids |
| • Low cost, easy to generate | • Low standardization |

| Advantages | Disadvantages |
|------------|--------------|
| • Retain molecular and histological features | • Lack of TME |
| • Suitable for high throughput studies | • High variability |
| • Creation of biobanks | • Time-consuming |

| Advantages | Disadvantages |
|------------|--------------|
| • Includes multiple cell populations | • Requires skill and experience |
| • Maintain cell viability over time | • Variation and inconsistency between different chips |
| • Suitable for drug screening | • Costly |

| Advantages | Disadvantages |
|------------|--------------|
| • Retain original tumor architecture | • Short lifespan |
| • Allow clinically relevant drug response studies | • Lack of reproducibility |
| • Relatively inexpensive | • Not for high throughput studies |

Fig. 2 Distinctive features of in vitro preclinical models. Features are divided into model-favoring characteristics and limiting factors. PDE patient-derived explants, TME tumour microenvironment. This figure was created with BioRender.com
or patient-derived EOC explants, without any requirement for deconstruction or reconstruction, offer a high content in vitro experimental platform, which can be successfully used both for exploring individualized treatment therapies and for studying cancer biology. On the other hand, these models lack a functional vasculature, have a short lifespan, and are expensive and difficult to maintain, and they are not suitable for high-throughput approaches (Fig. 2).

On the whole, in vitro and ex vivo preclinical approaches are all limited by their inability to reproduce the interplay among multiple systems, with significant disadvantages in the explorations of drug pharmacokinetics and pharmacodynamics. Therefore, in vivo models still keep a prominent place in EOC research (Fig. 3). In spite of this, translational EOC research field still lacks an animal model that is both robust and widely accessible, being well recognized that each model has its own advantages and disadvantages. The biological/clinical value of the different experimental approaches should be determined on a case-by-case basis to address specific issues, bearing in mind that the use of multiple models can increase confidence in study results. PDXS and GEMMS are the preferred in vivo research platforms for EOC, due to the limitations associated with cell line-derived xenografts [176]. Patient-derived xenografts largely maintain the characteristics of the patients’ original tumour including histology, mutational status, gene expression, and clinical behavior, while remaining generally stable throughout propagation, with marginal genetic drift at the time of PDX initiation and adaptation to mouse host. Therefore, PDX studies have proven effective in identifying clinically relevant biomarkers and in predicting human outcomes and response to conventional drugs in EOC therapy (Fig. 3). Importantly, different preclinical studies have confirmed the power of humanized mouse models for testing novel EOC immunotherapies, particularly in the emerging PDX platforms involving the engraftment of both tumour explants and immune cells from the same patient to establish a human immune system in the mouse host (Fig. 3). Their use is, however, currently limited by costs and relatively long and unpredictable times for establishing test animals.

### DISTINCTIVE FEATURES OF IN VIVO PRECLINICAL MODELS

| Advantages | Disadvantages |
|------------|---------------|
| Syngeneic  | • Limited number of murine cells |
|            | • Not capturing tumor heterogeneity |
|            | • Species-specific background |
| Xenografts | • Lack of host immune response |
| Cells engrafted can be genetically manipulated | • Limited cells tumorigenicity |
| Relatively inexpensive | • Non species-specific interaction between tumor and stroma |
| PDX | • Mostly retain molecular and histological features |
| Recapitulate TME | • Slow tumor growth |
| Suitable for drug screening | • Technical skills required |
| humPDX | • Powerfull tool for testing new immunotherapies |
| Recapitulate tumor processes | • Graft vs Host Disease |
| Autologous models highly relevant | • Autologous models challenging |
| GEMM | • Histologically and genetically accurate models |
| Presence of competent immune system | • Not capturing tumor heterogeneity |
| Powerful tool for studying tumor development | • Long latency to tumour development (overcome with EPO-GEMM) |
| Zebrafish | • Requires skill and experience |
| Monitoring tumor development | • Lack of standardized protocols and specific tools |
| Suitable for high throughput drug screening | • Different physiological conditions |
| Low-cost maintenance at high numbers | |
| Laying Hen | • Spontaneous development of cancer |
| Retain original tumor architecture | • Lack of standardized protocols and specific tools |
| Relatively inexpensive | • Lack of transgenic models |
| | • Species-specific background |

Fig. 3 Distinctive features of in vivo preclinical models. Features are divided into model-favoring characteristics and limiting factors. PDX patient-derived xenograft, humPDX humanized PDX, GEMMs genetically engineered mouse model, EPO-GEMM in vivo organ electroporation approach, TME tumour microenvironment. This figure was created with BioRender.com
On the other hand, transgenic murine models may recapitulate a specific cancer pathway, but fail to capture the true heterogeneity that is characteristic of human tumors. Other limitations include an extensive and costly breeding program and a variable latent period for tumor formation (up to 12 months in some instances) (Fig. 3).

In conclusion, no preclinical model can fully recapitulate the complexity of EOC within patients and their interindividual variability in drug response. A reasonable approach is to use a combination of in vitro, ex vivo, and in vivo experimental platforms to improve the predictive power of experimental systems, hopefully enhancing the impact of cancer research in EOC.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00018-022-04395-y.

Author contributions DG had the idea for the article; MB and AC performed the literature search and data analysis; MB and AC drafted the paper; AF, GS, and DG critically revised the work.

Funding Open access funding provided by Università Cattolica del Sacro Cuore within the CRUI-CARE Agreement.

Availability of data and materials Not applicable.

Declarations

Conflict of interest The authors have no relevant financial or non-financial interests to disclose.

Ethics approval and consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71:209–249
2. Kurnit KC, Fleming GF, Lengyel E (2021) Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol 137:108–121
3. Menon U, Gentry-Maharaj A, Burnett M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, Kalsi JK, Woolas R, Manchanda R, Arora R, Casey L, Dawny A, Dobbs S, Leeson S, Mould T, Seif MW, Sharma A, Williamson K, Liu Y, Fallowfield L, McGuire AJ, Campbell S, Skates SJ, Jacobs J, Parmar M (2021) Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 397:2182–2193
4. Prat J, D’Angelo E, Espinosa I (2018) Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 80:11–27
5. Lheureux S, Gourley C, Vergote I, Ozà AM (2019) Epithelial ovarian cancer. Lancet 393:1240–1253
6. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, Gottesman MM (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 108:18708–18713
7. Gillet JP, Varma S, Gottesman MM (2013) The clinical relevance of cancer cell lines. J Natl Cancer Inst 105:452–458
8. Maru Y, Hippo Y (2019) Current status of patient-derived ovarian cancer models. Cells 8:505
9. Robin T, Capes-Davis A, Bairouch A (2020) CLASTR: the cellosaurus STR similarity search tool—a precious help for cell line authentication. Int J Cancer 146:1299–1306
10. Beaufort CM, Helmijr JCA, Piskorz AM, Hoogstraat M, Ruigrok-Ristier K, Besselink N, Murtaza M, van IJcken WF, Heine AA, Smid M, Koudijis MJ, Brenton JD, Berns EM, Helleman J (2014) Ovarian Cancer Cell Line Panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One 9:e103988
11. Jacob F, Nixdorf S, Hacker NF, Heinzelmann-Schwarz VA (2014) Reliable in vitro studies require appropriate ovarian cancer cell lines. J Ovarian Res 7:60
12. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126
13. Anglesio MS,Wieand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG (2013) Type-specific cell line models for type-specific ovarian cancer research. PLoS One 8(9):e72162
14. Barnes BM, Nelson L, Tighe A, Burghel GJ, Lin IH, Desai S, McGrail JC, Morgan RD, Taylor SS (2021) Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes. Genome Med 13:140
15. Hennessy BT, Timmins KM, Carey MS, Gentry-Maharaj A, Rama N, Gravell BR, Flake DD 2nd, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broadrus DD, Lanchbury JS, Lu KH, Mills GB (2010) Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28:3570–3576
16. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615
17. Stronach EA, Alfraidi A, Rama N, Butler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H (2011) HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 71:4412–4422
18. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T (2009) Functional restoration of BRCA1 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69:6381–6386
19. Sun Y, Auersperg N (2019) Ovarian cancers: their varied origins and pathologically implicated microenvironment. In The Ovary. 3rd edn. Elsevier London, United Kingdom Chapter 32, pp 511–528
20. Zhang S, Dolgalev I, Zhang T, Ran H, Levine DA, Neel BG (2019) Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat Commun 10:5367
21. Shepherd TG, Thériault BL, Campbell EJ, Nachtigal MW (2006) Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protocol 1:2643–2649
22. Karst AM, Drapkin R (2012) Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protocol 7:1755–1764
23. Davies BR, Steele IA, Edmondson RJ, Zwiolinski SA, Saretski G, Von Zglinicki T, O’Hare MJ (2003) Immortalisation of human ovarian surface epithelium with telomerase and temperature-sensitive SV40 large T antigen. Exp Cell Res 288:390–402
24. Mitra A, Mishra L, Li S (2013) Technologies for deriving primary tumour cells for use in personalized cancer therapy. Trends Biotechnol 31:347–354
25. Pribyl LJ, Coughlin KA, Sueblinpong V, Shields K, Izuza Y, Downs LS, Ghebregziabher R, Bazzaro M (2014) Method for obtaining primary ovarian cancer cells from solid specimens. J Vis Exp 84:e51581
26. Cunnea P, Stronach EA (2014) Modeling platinum sensitive and resistant high grade serous ovarian cancer: development and applications of experimental systems. Front Oncol 4:81
27. Latifi A, Luwor RB, Bilandzic M, Nazaretni S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2011) Isolation and characterization of tumour cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 7:e46852012
28. Capellero S, Erriquez J, Battistini C, Porporato R, Scotto G, Borella F, Di Renzo MF, Valabrega G, Olivero M (2022) Ovarian cancer cells in ascites from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS One 93:528–542
29. Mikula-Pietrasik J, Rutecki S, Książek K (2022) The functional multipotency of transforming growth factor β signaling at the intersection of senescence and cancer. Cell Mol Life Sci 79:196
30. Zieba J, Ksiazkiewicz M, Janik K, Banaszczyk M, Peciak J, Piaskowski S, Lipinski M, Olczak M, Stoczynska-Fidelus E, Rieske P (2015) Sensitivity of neoplastic cells to senescence unveiled under standard cell culture conditions. Anticancer Res 35:2759–2768
31. O’Donnell RL, McCormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, Soohoo S, Elattar A, Curtin NJ, Edmondson RJ (2014) The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures of undergoing functional analysis. PLoS One 9(6):e90604
32. Auersperg N, Maines-Bandiera SL, Dyck HG, Kruk PA (1994) Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 71:510–518
33. Salamanca CM, Maines-Bandiera SL, Leung PC, Hu YL, Auersperg N (2004) Effects of epidermal growth factor/hydrocortisone on the growth and differentiation of human ovarian surface epithelium. J Soc Gynecol Invest 11:241–251
34. Ince TA, Sousa AD, Jones MA, Harrell JC, Agostos E, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekhbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugg J, Mills GB (2015) Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun 6:7419
35. Jensen C, Teng Y (2020) Is it time to start transitioning from 2D to 3D cell culture? Front Mol Biosci 7:33
36. Langhans SA (2018) Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol 9:6
37. Rodrigues J, Heinrich MA, Teixeira LM, Prakash J (2021) 3D in vitro model (R)evolution: unveiling tumour-stroma interactions. Trends Cancer 7:249–264
38. Sutherland RM (1988) Cell and environment interactions in tumour microregions: the multicell spheroid model. Science 240:177–184
39. Friedlich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4:309–324
40. Hereda-Soto V, Redondo A, Berjón A, Miguel-Martín M, Díaz E, Crespo R, Hernández A, Yébenes L, Gallego A, Feliú J, Hardisson D, Mendiola M (2018) High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease. Oncotarget 9:21893–21903
41. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, Skubitz AP (2004) Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 93:170–181
42. Lee JM, Mhawech-Fauceglia P, Lee N, Parsian LC, Lin YG, Gayther SA, Lawrenson K (2013) A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. Lab Invest 93:528–542
43. Shield K, Ackland ML, Ahmed N, Rice GE (2009) Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecol Oncol 113:143–148
44. Alkema NG, Wissman GB, van der Zee AG, van Vugt MA, de Jong S (2016) Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updat 24:55–69
45. Long L, Hu Y, Long T, Lu X, Tuo Y, Li Y, Ke Z (2021) Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer. J Immunother Cancer 9:e003973
46. Ciucci A, Zannoni GF, Buttarelli M, Lisi L, Travaglia D, Martinelli E, Scambia G, Gallo D (2016) Multiple direct and indirect mechanisms drive estrogen-induced tumour growth in high grade serous ovarian cancers. Oncotarget 7:8155–8171
47. Ciucci A, Zannoni GF, Buttarelli M, Martinelli E, Mascilini F, Petrillo M, Ferrandina G, Scambia G, Gallo D (2016) Ovarian low and high grade serous carcinomas: hidden divergent features in the tumour microenvironment. Oncotarget 7:68033–68043
48. Nowak M, Klink M (2020) The role of tumour-associated macrophages in the progression and chemoresistance of ovarian cancer. Cells 9:1299
49. Clevers H (2016) Modeling development and disease with organs. Cell 165:1586–1597
50. NERO C, Vizzigli S, Loruso D, Cesari E, Daniele G, Loverro M, Scambia G, Sette C (2021) Patient-derived organoids and high
grade serous ovarian cancer: from disease modeling to personalized medicine. J Exp Clin Cancer Res 40:116
52. Yang J, Huang S, Cheng S, Jin Y, Zhang N, Wang Y (2021) Application of ovarian cancer organoids in precision medicine: key challenges and current opportunities. Front Cell Dev Biol 9:701429
53. Kopper O, de Witte CJ, Lohmuussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, van Wijk LM, Revilla SA, van de Ven M, van Roosmalen MJ, Ponsioen B, Ho VW, Heel BG, Bosse T, Garenstenroom KN, Vriezing H, Vreeswijk MPG, van Dien PJ, Witteveen PO, Jonges T, van Oudenaarden A, Zweemer RP, Snippert HJG, Kloosterman WP, Clevers H (2019) An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med 25:838–849
54. Hoffmann K, Berger H, Kalbe H, Thillainadarasam S, Mollkenkopf H, Zemojtel T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J, Chekerov R, Braicu EI, Meyer TF, Kessler M (2020) Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment. EMBO J 39:e104013
55. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Shoner A, Sailer V, Angelillo M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gori VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA (2017) Personalized in vitro and in vivo Cancer models to guide precision medicine. Cancer Discov 7:462–477
56. Phan N, Hong JJ, Totig B, Mapua M, Elashoff D, Moatamed NA, Huang J, Menarzadeh S, Damaoises R, Soragini A (2019) A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumour organoids. Commun Biol 2:78
57. Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ (2021) Patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. J Exp Clin Cancer Res 40:338
58. Surendran V, Rutledge D, Colton R, Chandrasekarana A (2021) A novel tumour-immune microenvironment (TIME)-on-Chip mimics three dimensional neutrophil-tumour dynamics and neutrophil extracellular traps (NETs)-mediated collective tumour invasion. Biofabrication 13(5):956-76. Brückner L, Reinshagen A, Hoang NA, Höhn AK, Lordick F, Ramzan AA, Bitler BG, Hicks D, Barner K, Qamar L, Behbakht B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Elemento O, Beltran H, Demichelis F, Kemp CJ, Grandori C, Cantley LC, Rubin MA (2017) Personalized in vitro and in vivo Cancer models to guide precision medicine. Cancer Discov 7:462–477
59. Sun B, Mathur T, Tronolone JJ, Chokshi M, Lokhande GK, Selahi A, Gaharwar AK, Afshar-Kharghan V, Sood AK, Jain A (2020) OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer. Blood Adv 4:3329–3342
60. Saha B, Mathur T, Tronolone JJ, Chokshi M, Lokhande GK, Selahi A, Gaharwar AK, Afshar-Kharghan V, Sood AK, Bao G, Jain A (2021) Human tumour microenvironment chip evaluates the consequences of platelet extravasation and combinato-rial antitumor-antiplatelet therapy in ovarian cancer. Sci Adv 7:eabc5283
61. Ricciardelli C, Lokman NA, Sabit I, Gunasegaran K, Bonner WM, Pyragius CE, Macpherson AM, Oehler MK (2018) Novel ex vivo ovarian cancer tissue explant assay for prediction of che-moresitvity and response to novel therapeutics. Cancer Lett 461:51–58
62. Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBragliato AF, Buchsbaum DJ (2007) Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 105:291–298
63. Frederick PJ, Kendrick JE, Straughn JM Jr, Della Manna DL, Oliver PG, Lin HY, Grizzle WE, Stockard CR, Alvarez RD, Zhou T, LoBragliato AF, Buchsbaum DJ (2009) Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Int J Gynecol Cancer 19:814–819
64. Ramzan AA, Biter BG, Hicks D, Barner K, Qamar L, Behbakt K, Powell T, Jansson T, Wilson H (2019) Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Mol Cell Biochem 461:37–46
65. Brückner L, Reinshagen A, Hoang NA, Höhn AK, Lordick F, Bechmann I, Aktas B, Niel K, Kallendrusch S (2021) FOX1 inhibition in ovarian cancer tissue cultures affects individual treatment susceptibility ex vivo. Cancers (Basel) 13(5):956
66. Vaira V, Fedele G, Pyne S, Fasoli E, Zadrz G, Bailey D, Snyder E, Faversani A, Coggia G, Flavin R, Bosari S, Loda M (2010)
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci U S A 107:8352–8356

78. Templeton AR, Jeffery PL, Thomas PB, Perera MPJ, Ng G, Calabrese AR, Nicholls C, Mackenzie NJ, Wood J, Bray LJ, Vela I, Thompson EW, Williams ED (2021) Patient-derived explants as a precision medicine patient-proximal testing platform informing cancer management. Front Oncol 11:767697

79. Hoffman RM (1991) Three-dimensional histoculture: origins and applications in cancer research. Cancer Cells 3:86–92

80. Nakada S, Aoki D, Ohie S, Horiuichi M, Suzuki N, Kanasugi M, Susumii N, Udagawa Y, Nozawa S (2005) Chemosensitivity testing of ovarian cancer using the histocyte drug response assay: sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 15:445–452

81. Jung PS, Kim DY, Kim MB, Lee SW, Kim JH, Kim YM, Kim YT, Hoffman RM, Nam JH (2013) Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histocyte drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res 33:1029–1034

82. Lee J, Kim JM, Lee YH, Chong GO, Hong DG (2021) Applicability of the histoculture drug response assay to predict platinum sensitivity and prognosis in ovarian cancer. Anticancer Res 41:6287–6292

83. Abreu S, Silva F, Mendes R, Mendes TF, Teixeira M, Santo VE, Boghaert ER, Félix A, Brito C (2020) Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures. Sci Rep 10:19462

84. Mittal S, Gupta P, Chaluvally-Raghavan P, Pradeep S (2022) Establishment of in vivo ovarian cancer mouse models using intraperitoneal tumour cell injection. In: Kreeger PK (ed) Ovarian cancer. Methods in molecular biology, vol 2424. Humana, New York

85. Popa M, Fosse V, Kleinmanns K, Bjoerke L, McCormack E (2022) Xenograft models of ovarian cancer for therapy evaluation. In: Kreeger PK (ed) Ovarian cancer. Methods in molecular biology, vol 2424. Humana, New York

86. Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17:279–284

87. Sallinen H, Anttila M, Narvainen J, Ordén MR, Ropponen K, Kosma VM, Heinonen S, Yla-Herttuala S (2006) A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol 103:315–320

88. De Haven BA, Box G, Hallsworth A, Court W, Matthews N, Herodock B, Arteagabeitia AB, Valenti M, Kirkin V (2020) Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice. Sci Rep 10:107999

89. Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, Wallace J (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58:109–113

90. Nishida T, Sugiyama TO, Kataoka A, Ushijima K, Yukashii M (1998) Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7,12-dimethylbenz[a]anthracene-coated suture. Cancer 83:965–970

91. Stewart SL, Querci TD, Ochman AR, Gruver BN, Bao R, Babb JS, Wong TS, Koutroukides T, Pinnola AD, Klien-Szanto A, Hamilton TC, Patriots C (2004) Characterization of a carcinogenesis rat model of ovarian preneoplasia and neoplasia. Cancer Res 64:8177–8183

92. Tanaka T, Kohno H, Suzuki R, Sugie S (2004) Lack of modifying effects of an estrogenic compound atrazine on 7,12-dimethylbenz[a]anthracene-induced ovarian carcinogenesis in rats. Cancer Lett 210:129–137

93. Crist KA, Zhang Z, You M, Gunning WT, Conran PB, Steele VE, Lubet RA (2005) Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. Carcinogenesis 26:951–957

94. Ting AY, Kimler BF, Fabian CJ, Petroff BK (2007) Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis 28:130–135

95. Yang XY, Li Y, Cai SQ, Wang L, Qiang JW (2021) Optimization of 7,12-dimethylbenz[a]anthracene-induced rat epithelial ovarian tumors. Oncol Lett 21:206

96. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF (2000) Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 21:585–591

97. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, Allman D, Coukos G (2002) Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 161:2295–2309

98. Janat-Amsbury MM, Yockman JW, Anderson ML, Kieback DG, Kim SW (2006) Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res 26:2785–2789

99. Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vossden K, Lockley M, McNeill IA (2016) Crisp/Cas9-mediated Trp53 and Brc2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res 76:6118–6129

100. Walton JB, Farquharson M, Mason S, Port J, Krupsig B, Dowson S, Stevenson D, Murphy D, Matzuk M, Kim J, Coffelt S, Blyth K, McNeill IA (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brc1, Pten and Nf1, and correlation with platinum sensitivity. Sci Rep 7:16827

101. Morse CB, Voillette B, Bates BM, Chiu EY, Garcia NM, Gottardo R, Greenberg PD, Anderson KG (2021) Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease. Gynecol Oncol 160:427–437

102. Greenaway J, Moorehead R, Shaw P, Petrik J (2008) Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol 108:385–394

103. Iyer S, Zhang S, Yucel S, Horn H, Smith SG, Reinhardt F, Hoefsmitt E, Assatova B, Casado J, Meinsohn MC, Barrasa MI, Bell GW, Pérez-Villatoro F, Huithtien K, Hynninen J, Okkonen J, Galhenage PM, Pathania S, Hammond PT, Neel BG, Farrkila A, Pépin D, Weinberg RA (2021) Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy. Cancer Discov 11:384–407

104. Okada S, Vaateewootacharn K, Kariya R (2019) Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells 8:889

105. Mullen P, Ritchie A, Langsdon SP, Miller WR (1996) Effect of matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int J Cancer 67:816–820

106. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC (2004) Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10:1032–1042

107. Mitra AK, Davis DA, Tomar S, Roy L, Gurler H, Xie J, Lantvit DD, Cardenas H, Fang F, Liu Y, Loughran E, Yang J, Sharon Stack M, Emerson RE, Cowden Dahl KD, Barbolina
108. Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, Annunziata CM (2016) Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol 142:332–340

109. De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, Baroni S, Renier D, Scambia G, Ferlini C, Gallo D (2011) Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol 68:107–116

110. Ciucci A, Zannoni GF, Travaglia D, Petrollo M, Scambia G, Gallo D (2014) Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serious ovarian cancer. Gynecol Oncol 132:351–359

111. Buttarelli M, De Donato M, Raspaglio G, Babini G, Ciucci A, Martinelli E, Baccaro P, Pasciuto T, Fagotti A, Scambia G, Gallo D (2020) Clinical value of IncRNA MEG3 in high-grade serous ovarian cancer. Cancers (Basel) 12:966

112. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Slamon D, Karlan BY (2002) A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol 87:200–206

113. Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, McShane L (2017) Establishment of patient-derived tumour xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res 23:1263–1273

114. Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN (2014) Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget 5:8750–8764

115. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE (2011) Phenotypic heterogeneity and instability of human ovarian tumour-initiating cells. Proc Natl Acad Sci USA 108:6468–6473

116. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ (2005) Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol 96:48–55

117. Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE, Song SY, Choi JJ, Bae DS, Lee YY, Choi CH, Kim TJ, Park WY, Kim BG, Lee JW (2017) Patient-derived xenograft models of epithelial ovarian cancer for preclinical studies. Cancer Res Treat 49:915–926

118. Eoh KJ, Chung YS, Lee SH, Park SA, Kim HJ, Yang W, Lee IO, Lee JY, Cho H, Chay DB, Kim S, Kim SW, Kim JH, Nam EJ (2018) Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenografts. Cancer Res Treat 50:956–963

119. Brook G, Livingston DM, Brugge JS, Matulonis UA, Drapkin R, Mills GB, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf MV, Nephew KP, Matei D, Burdette JE (2015) In vivo tumour growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol 138:372–377

120. Cybula M, Wang L, Wang L, Drumond-Bock AL, Motley KM, Benbrook DM, Gunderson-Jackson C, Ruiz-Echevarria MJ, Bhattacharya R, Mukherjee P, Bieniasz M (2021) Patient-derived xenografts of high-grade serous ovarian cancer subtype as a powerful tool in pre-clinical research. Cancers (Basel) 13:6288

121. Butler KA, Hou X, Becker MA, Zanfagnin V, Enderica-Gonzalez S, Visscher D, Kalli KR, Tietchenabada P, Haluska PS, Weroja SJ (2017) Prevention of human lymphoproliferative tumour formation in ovarian cancer patient-derived xenografts. Neoplasia 19:628–636

122. Isumchenko E, Paz K, Cizmadjia D, Sloma I, Katz A, Vaszquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidiransky D (2017) Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann Oncol 28:2595–2605

123. Liu Y, Chanana P, Davila JL, Hou X, Zanfagnin V, McGehee CD, Goele E, Polley EC, Haluska PS, Weroja SJ, Wang C (2019) Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Sci Rep 9:6314

124. Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R, Golub TR (2017) Patient-derived xenografts undergo mouse-specific tumour evolution. Nat Genet 49:1567–1575

125. Chen J, Jin Y, Li S, Qiao C, Peng X, Li Y, Gu Y, Wang W, You Y, Yin J, Shan Y, Wang YX, Qin M, Li H, Cai Y, Dong Y, Peng S, Pan L (2021) Patient-derived xenografts are a reliable preclinical model for the personalized treatment of epithelial ovarian cancer. Front Oncol 11:744256

126. Colono-Otero G, Weroha SJ, Foster NR, Haluska PS, Hou X, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA, Wahner-Hendrickson AE, Jatoi A, Block MS, Dinh TA, Robertson MW, Copland JA (2017) Phase 2 trial of velvotam and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol 146:64–68

127. Colono-Otero G, Zanfagnin V, Hou X, Foster NR, Asmus EJ, Wahner Hendrickson A, Jatoi A, Block MS, Langstraat CL, Glaser GE, Dinh TA, Robertson MW, Camoriano JK, Butler KA, Copland JA, Weroha SJ (2020) Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open 5(5):e000926

128. Comte N, Mason JC, Halmguy C, Neuhausser S, Mosaka A, Yordanova G, Chatzipili A, Begley DA, Kuprde DM, Parkison H, Meehan TF, Bult C (2019) PDX Finder: a portal for patient-derived tumour xenograft model discovery. Nucleic Acids Res 47:D1073–D1079

129. Yin L, Wang JX, Chen DX, Liu XN, Wang JX (2020) Humanized mouse model: a review on preclinical applications for cancer immunotherapy. Am J Cancer Res 10:4568–4584

130. Magnotti E, Marasco WA (2018) The latest animal models of ovarian cancer for novel drug discovery. Expert Opin Drug Discov 13:249–257
134. Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, Feng F, Liu Y, Xu W, Li Y (2019) Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoreistant phenotype. J Exp Clin Cancer Res 38:81

135. Bankert RB, Balu-iyer SV, Odunsi K, Shultz LD, Kelleher RJ Jr, Barnas JL, Simpson-Abelson M, Parsons R, Yokota SJ (2011) Humanized mouse model of ovarian cancer recapitulates patient solid tumour progression, ascites formation, and metastasis. PLoS One 6(9):e24420

136. Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA (2015) Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumour-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology 5:e1000075

137. Giotto SB, Kim H, Rafael S, Omran DK, Medvedev S, Kinose Y, Rodriguez-Garcia A, Flowers AJ, Xu H, Schwartz LE, Powell DJ Jr, Simpkins F (2020) An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer. Gynecol Oncol 156:222–232

138. Howell VM (2014) Genetically engineered mouse models for epithelial ovarian cancer: are we there yet? Semin Cell Dev Biol 27:106–117

139. Zakarya R, Howell VM, Colvin EK (2020) Modelling epithelial ovarian cancer in mice: classical and emerging approaches. Int J Mol Sci 21:4806

140. Kim J, Park EY, Kim O, Schilder JM, Coffey DM, Cho CH, Ho YJ, Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA (2015) Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumour-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology 5:e1000075

141. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC (2003) Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIR promoter develop epithelial ovarian cancer. Cancer Res Mar 63:1389–1397

142. Arroyo J, Hahn W (2005) Involvement of PP2A in viral and non-viral senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc Natl Acad Sci USA 119:e211754119

143. Orslic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varus HE (2002) Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53–62

144. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63–70

145. Xing D, Orslic S (2006) A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 66:8949–8953

146. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 11:321–333

147. Mullany LF, Fan HY, Liu Z, White LD, Marshall A, Gunaratne P, Anderson ML, Creighton CJ, Xin L, Deavers M, Wong K, Richards JS (2011) Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene 30:3522–3536

148. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM (2012) High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109:3921–3926

149. Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Iveta I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Chris-tensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA (2012) An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122:552–557

150. Szabova L, Yin C, Bupp S, Guerin TM, Schlomer JJ, Householder DB, Baran ML, Yi M, Song Y, Sun W, McDunn JE, Martin PL, Van Dyke T, Difilippantonio S (2012) Perturbation of rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 72:4141–4153

151. Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IM (2014) Roles of deletion of Arid1a, a tumour suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst 106:duj146

152. Ren YA, Mullany LK, Liu Z, Herron AJ, Wong KK, Richards JS (2016) Mutant p53 promotes epithelial ovarian cancer by regulating tumour differentiation, metastasis, and responsiveness to steroid hormones. Cancer Res 76:2206–2218

153. Zhai Y, Kuick R, Tipton C, Wu R, Sensine M, Wang Z, Baker SJ, Fearon ER, Cho KR (2016) Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival. J Pathol 238:21–30

154. Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hiranai P, Joy JD, Szabova L, Perets R, Sansom OJ, Drapkin R, Bailey P, Balkwill FR (2020) Mouse ovarian cancer models recapitulate the human tumour microenvironment and patient response to treatment. Cell Rep 30:525–540 (e7)
164. Johnson PA, Giles JR (2013) The hen as a model of ovarian cancer. Nat Rev Cancer 13:432–436
165. Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL (2009) Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. Int J Gynecol Cancer 19:531–539
166. Paris EA, Bahr JM, Bitterman P, Basu S, Abramowicz JS, Barua A (2021) Incidence of malignant transformation in the oviductal fimbria in laying hens, a preclinical model of spontaneous ovarian cancer. PLoS One 16(7):e0255007
167. White R, Rose K, Zon L (2013) Zebrafish cancer: the state of the art and the path forward. Nat Rev Cancer 13:624–636
168. Gamble JT, Elson DJ, Greenwood JA, Tanguay RL, Kolluri SK (2021) The zebrafish xenograft models for investigating cancer and cancer therapeutics. Biology (Basel) 10(4):252
169. Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, McLaren K, Matthews L, McLaren S, Sealy I et al (2013) The zebrafish reference genome sequence and its relationship to the human genome. Nature 496:498–503
170. Kirchberger S, Sturtzel C, Pascoal S, Distel M (2017) Quo natus, diano?): Recent progress in modeling cancer in zebrafish. Front Oncol 7:186
171. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2011) Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 112:2850–2864
172. Wang X, Xu X, Jiang G, Zhang C, Liu L, Kang J, Wang J, Owusu L, Zhou L, Zhang L, Li W (2020) Dihydotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. J Cell Mol Med 24:11177–11187
173. Fieuws C, Vierstraete J, Van De Vijver K, Denys H, Claes KBM (2020) Isolation and engraftment of circulating tumour cells into zebrafish embryos to predict tumour response of ovarian cancer patients [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13–16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 26(11_suppl):Abstract nr B25
174. Barriuso J, Nagaraju R, Hurlstone A (2015) Zebrafish: a new companion for translational research in oncology. Clin Cancer Res 21:969–975
175. Buttarelli M, Ciucci A, Palluzzi F, Raspaglio G, Marchetti C, Perrone E, Minucci A, Giacò L, Fagotti A, Scambia G, Gallo D (2022) Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. J Exp Clin Cancer Res 41:50
176. Tudrej P, Kujawa KA, Cortez AJ, Lisowska KM (2019) Characteristics of in vivo model systems for ovarian cancer studies. Diagnostics (Basel) 9(3):120–154

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.